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ABSTRACT 
 
 
Background: The D-Dimer test has a high negative predictive value used primarily to 
exclude clinically suspected possible thrombo-embolic disease. In Emergency Unit (EU) 
practice, this test is often done not only for suspected Pulmonary Emboli (PE) but also to 
rule out atypical PE. In South Africa, diagnostic usefulness of this test has not been 
evaluated in a private hospital EU. The health profile of patients presenting in public and 
private EUs is different and therefore, it was hypothesized that the usefulness of the D-
Dimer test in these two settings may be different. Results of this study may inform private 
hospital EU best practice in the optimal utilization of this test. 
Objective: To evaluate the usefulness of the D-Dimer test in the diagnosis of PE at the 
Morningside MediClinic (MMC) private hospital EU in Johannesburg, South Africa. 
Patients and Methods: After approval by the University of the Witwatersrand Human 
Research Ethics Committee, audit of clinical records was done at the MMC EU from 1 
March to 1 June 2009. Informed consent was not required from study subjects as the study 
was done retrospectively with data extracted from clinical records in an anonymous and 
delinked fashion. The study population included all patients who had a D-Dimer test done 
in the MMC EU as part of their diagnostic workup. Extracted data included demographic 
information, diagnoses and confirmatory tests done. Continuous and categorical variables 
of data collected were summarized using Stastistica version 9.0 statistical package. A 
Wells Score was calculated according to the Wells Criteria. 
Results: In the study period, 189 of 2948 (5%) patients seen at MMC EU had D-Dimers 
measured. Their population mean age was 57 years (range 38 – 84 years) and 51% were 
males. Positive D-Dimers were present in 40 (21%) of the total patient population sample 
group (189 patients). Within the diagnostic categories, the following percentages were the 
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results found per category of the positive D-Dimers within each category: PE (5)(100%), 
Chest Infection (5)(56%), AMI (2)(33%), Arrhythmia (2)(33%), Hypertension (2)(25%), 
Chest Pain (6)(14%), Anxiety (3)(23%), Headache (1)(14%), Syncope (1)(14%) and 
Others (13)(32%). The mean Wells Score in PE was 3.6 (3.0-4.5.) indicating medium 
probability of PE. All other diagnostic groups had low probability Wells Scores. It was 
impossible to comment on findings in public hospitals, as there is no known literature 
found to date on an audit performed concerning the usefulness of the D-Dimer test in a 
public hospital or any of the public sector, in Johannesburg or elsewhere in South Africa, 
regarding the diagnosis of PE. However, data has been published by other countries 
regarding the D-Dimer in various hospital and EU settings (public and private). 
Conclusion: In the cohort, the D-Dimer was done in only a fifth of patients seen at the 
private MMC EU and it was positive in less than half of cases. The test yield was highest 
in PE and had high negative predictive value in more than half of non-PE diagnoses. 
Therefore, the results suggested that a positive D-Dimer is highly predictive of a diagnosis 
of PE in this private EU. A negative D-Dimer result appears to be largely associated with 
any of the non PE wide differential of diagnoses. 
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INTRODUCTION 
 
1.0  PULMONARY EMBOLI 
 
1.1 Pulmonary Emboli epidemiology 
 
Pulmonary Emboli (PEs) are common and have been increasing in incidence in 
the adult age group,1,2 with just over half a million patients being diagnosed per 
annum in the USA.3-5 They are however uncommon in the paediatric population,3 
whilst they occur in all ages and sexes, there is an association between increasing 
age and PEs in both sexes. The latter observation may in part be due to the 
presence of more risk factors with increasing age.6,7 Elderly patients that have 
been hospitalised have been found to commonly suffer from fatal PEs, often only 
diagnosed at post-mortem examination.6,7  
 
Evidence also shows that females are less likely to have a second episode of 
Pulmonary Embolism (PE), however the risk is increased during pregnancy and 
postpartum.8 Studies have documented a higher mortality (20-30%), among male 
patients with a PE, compared to females.8 In terms of ethnicity, Africans have a 
50% higher probability of thrombotic illness and 50% increase risk of death, 
compared to Caucasians. Caucasians have a 50% higher probability of PE as well 
as risk of death compared to other races like, American Indians and Asians, 
however, this observation may partly be due to reporting bias as very few studies 
have been done in Africa and Asia.6-8   
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There are many other factors such as immobilisation, previous major surgery, 
malignancy, pregnancy and protein C or S deficiency, that increase the risk of an 
individual’s susceptibility to a PE.9 PEs are associated with high mortality, which 
may reach 50 - 200 000 a year.1-3 
 
In Emergency Units (EUs), the frequency of PE has increased with atypical 
presentations more frequent with consequent greater morbidity and mortality due 
to missed diagnoses.10-12 Diagnosis of PE is often complex, requiring an array of 
diagnostic modalities including clinical, radiological and blood investigations.13-15 
 
1.2 Pathogenesis of PE 
• Virchow’s Triad - Virchows’ triangle is the term that refers to the triad of 
immobility/venous stasis, vascular injury/inflammation and propensity for 
clotting (Hypercoagulability), which encompasses both hereditary and 
acquired factors.3,4,14 
Immobility/venous stasis, refers to disruptions in the normal circulation which 
can occur as a result of turmulous blood flow, varicosities as well as cardiac 
conditions like mitral stenosis, pregnancy and vessel valve compromise, to 
name a few predisposing conditions.16,17 The lower limb venous system is a 
low pressure system, composed of superficial and deep vasculature and inter-
connecting veins. The latter blood flow depends on the lower limb muscle 
activity, which is affected by an individual’s activity or the lack of it, 
especially when for example, bedridden post-surgery.17 
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Vascular injury/inflammation refers to any form of damage to the vessel 
endothelium such as injury from traumatic shearing and surgical procedures 
(angiogram, Central Venous Percutaneous catheterisation (CVP)), high blood 
pressure, any foreign matter including infective and/or medical equipment 
(pace maker), or any other condition that causes stress or irritation of the 
vasculature.16,17 
 
Any changes in the composition of the blood, affecting the hypercoagulability, 
can be caused by numerous factors including pregnancy, age, smoking, 
clotting factor abnormalities, non-O blood types, burns, renal pathologies, 
malignancies, and oestrogen based medicines, among many other 
conditions.16,17 
 
• Promoting and risk factors - Age (especially >40 years),4,10,14 sex and 
ethnicity have importance when considering risk factors involved in PE and 
Deep Vein Thrombosis (DVT) occurrence.2,8,18 
 
Other factors placing an individual at risk include air or road travel (more 
commonly with air travel), involving four or more hours in the month prior to 
the patient’s initial symptoms, can also result in a DVT/PE due to venous stasis 
as a result of immobility.4,5 
 
Various conditions such as polycythaemia, dehydration, smoking, a tumour 
compressing venous circulation externally, any form of cancer, previous 
PE,4,10,14  and extended periods of sitting in front of a computer, cause a build-
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up of clotting factors and fibrin which increases the formation of thrombin 
often with a resultant clot.4,19 
 
The incidence of PE is much higher in the African as opposed to the 
Caucasians, with an increased risk of death of 50% compared to a similar 
Caucasians with PE.8,18  However, the Caucasians have a higher risk of PE as 
well as 50% likelihood of death compared to other races such as Asians and 
Native Americans.8,18 There is conflicting information regarding males being 
at higher risk for PE although mortality has been found higher among men 
than in women (20-30%).8,18 
 
In a recent study, female patients younger than 65 years, with idiopathic 
venous thrombo-embolic disease with a normal range D-Dimer result, four 
weeks after stopping their anti-coagulation therapy, were at very low risk of 
recurrence of the thrombotic episode.7,20 
 
• VQ mismatch – It has recently been proposed that approximately 50% of 
patients suffering from thrombotic pathology may have a ventilation/perfusion 
abnormality. There is a debate whether the fatality from PE is related to 
haemodynamic abnormalities, Oxygen/Carbon dioxide (O2/CO2) gaseous 
exchange or other endocrine factors.21 Several important reasons for 
compromised circulation include an anatomical cause of obstruction followed 
by other vasoactive substances which can affect the interpretation of 
Ventilation Perfusion (VQ) ratio such as serotonin.4,6,10 Around 50% of the 
blood flow through the lungs would need to be compromised by a PE before 
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this would result in significant pulmonary vascular obstruction since a healthy 
individual is able to double their cardiac output without major local effect on 
arterial pressures in response to such a mechanical threat.21 Thrombotic lung 
disease alters lung tissue by changing the usual functioning components into 
areas of anatomical “dead space”. The latter results in blood gas arterial 
abnormalities due to the changes in partial arterial oxygen pressure (PaO2) and 
partial arterial carbon dioxide pressure (PaCO2) (VQ mismatch), which will be 
evident in the patient’s clinical presentation.21  
 
• Local effect of an embolus on pulmonary circulation - A PE is a clot that is 
formed somewhere in the body and moves to the lungs, which can obstruct the 
flow of blood in the cardiopulmonary circulation.11 This is commonly the 
result of migration of a blood clot originating in the deep vessels of the lower 
limbs or pelvis.11  
 
The most common origin of a PE is in the lower limb calf veins near valves 
where there is less dynamic flow.4,10 Other less common sites of origin of a PE 
include haemorrhoidal vasculature and the Superior Vena Cava (SVC),3 or 
may arise in the lungs, or travel from the right side of the heart to reach the 
lungs.4,6,11  
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Figure 1.1 The pathophysiology of pulmonary embolism. Although pulmonary embolism 
can arise from anywhere in the body, most commonly it arises from the calf veins. The 
venous thrombi predominately originate in venous valve pockets (inset) and at other sites 
of presumed venous stasis. To reach the lungs, thrombo-emboli travel through the right 
side of the heart. RA, right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle. 
Sutherland SF. Pulmonary Embolism. (Image reprinted with permission from 
eMedicine.com, 2010.6) 
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1.3 Risk Factors for PE 
 
These can be acquired or hereditary and can help in guiding the Health Care 
Provider (HCP) in their choice of further investigations and prophylactic 
measures.3,4,14,18 
 
1.3.1 Acquired risk factors 
 
o Trauma - Especially recent trauma (last three months), where venous 
injury may have occurred, increases clotting factors as well as may 
confine a patient to bed rest thereby increasing their risk of forming a 
DVT/PE.18,22,23  
 
In the literature, major trauma has been associated with 58% risk of DVT 
in the lower limbs, and an 18% risk of the latter being found in the 
proximal circulation.22  
 
• Limbs - Fractures of the femur and tibia, pelvis, vertebrae, as well as 
amputations involving limbs, have been documented to have a higher 
risk of associated PE, as well as total hip and knee replacements and 
spinal cord injuries can predispose to PE and DVT.4,18  
 
• Burns - Major burns increase the risk of hypercoagulable state and 
therefore PE and DVT.18 This has been supported by various studies 
 8 
 
where burns of the peripheries (limbs), appeared to be a risk factor for 
the formation of DVT. In a particular study, there was a 2.4% 
incidence (8 patients with DVT and 2 with PE out of 327 adult burn 
patients).24 These appeared to occur in veins draining from the area of 
burnt tissue in these peripheral areas.24 
 
• Other - Other concerns are in patients suffering from cancers of 
pancreatic, lung, urological, gastric and breast origin, in descending 
order of occurrence (increased risk by 17%), as well as patients with 
decreased mobility (for example bed rest as a result of injury or a limb 
cast placed peripherally), as well as those suffering from acute 
medical illness such as,4,19 increased venous pressure as in Congestive 
Cardiac Failure (CCF), hypotension and paralysis.11,18 Obesity also 
alters the fine equilibrium of coagulation.18,22,23  
 
Recent central venous catheterisation (last three months),18,23 
Cerebrovascular Accidents (CVA), previous PE or Chronic 
Obstructive Pulmonary Disease (COPD), varicose veins and 
Inflammatory Bowel Syndrome (IBS), are some of the medical and 
surgical risk factors. Current or past thrombophlebitis, within the last 
three months is another risk factor.18,23 This is due to an enhanced 
inflammation and activation of blood coagulation factors.2,18,25 
 
Antiphospholipid Antibodies (APLA) – This syndrome implies the 
presence of a hypercoagulable state which is linked with the presence 
of APLA causing Antiphospholipid Syndrome (APS). The latter has 
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been linked with autoimmune pathologies but has also commonly 
been linked to various viral infections such as Human Parvovirus B19 
which can imitate autoimmune diseases resulting in DVT/PE. 
Cytomegalovirus (CMV) has also been linked with APLA/APS.26 
Both viral infections are hypothesised to have been responsible for 
thrombotic events through several mechanisms involving molecular 
mimicry.26  
 
Stem cell transplant – This is associated with an increased clotting 
risk in the post-transplantation state. This thrombotic risk may change 
according to the pre-transplant cell preparatory regimens used, the 
type of transplant, any underlying chronic disorder and possible 
medication post-transplantation.14,27 The increased use of 
haematopoietic growth factors used to treat cytopaenias in order to 
mobilise stem cells, is for example, thought to be one of the causes of 
the latter thrombotic events.14 
 
o Surgery – Surgery affects the clotting factors.18,22,23 There have been 
reports of up to 15% increased risk post-operatively of PE.18,19 Post-
operative (hip and knee replacements/abdominal procedures) or 
immobile patients also show a high propensity of clotting abnormalities 
such as DVT and PE.3,13 
 
o Pregnancy – This is one of the hypercoagulable states which, interferes 
with the very fine equilibrium between coagulation and anticoagulation. 
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There is an increased risk of thrombosis in pregnancy in the antepartum 
stage where sudden miscarriage has been linked with APLA (see below), 
which are associated with clotting, as well as during the postpartum state, 
due to factors which cause hypercoagulability among which is an 
increase in platelet count.4,18  The prevalence has been documented to 
range from 1 in 200 deliveries to 1 in 1400 with fatality documented as 1 
- 2 cases per 100 000 pregnancies.18 
 
o Sepsis – Sepsis alone as well as its serious complication – DIC, 
resembles other inflammatory disorders in which an on-going stimulus is 
responsible for constant activation of blood coagulation, resulting in on-
going thrombin and therefore fibrin production which depletes the 
normal clotting factors including inhibitors.2 
 
o Drugs – Oral contraceptives, especially when combined with smoking.4,5 
and hormone replacements (oestrogen) in healthy females, triple the risk 
(20 - 30 cases per 100 000 per year).18,19  Chemotherapy and 
immunotherapy have been associated with increase clotting. There have 
been studies done involving the relationship of thrombosis with 
thalidomide treatment in multiple myeloma. Also other cytotoxic and 
immuno-therapies can increase thrombotic tendency in malignancy.28,29  
Heparin preparations have also been noted to be linked with an increased 
risk of thrombosis.4 
 
o Disseminated Intravascular Coagulation (DIC) – This is a serious and 
fairly common complication of a number of disorders, mainly 
septicaemia, cancer, obstetric pathologies as well as other inflammatory 
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pathologies, which cause continuous activation of the blood coagulation 
pathways. This, results in on-going intravascular thrombin and fibrin 
production, which eventually results in consumption of all clotting 
factors and their inhibitors, resulting in a clotting and/or haemorrhagic 
event. It is therefore essential to diagnose DIC as early as possible, so as 
to be able to begin appropriate treatment, mainly related to the 
elimination of the causative agent or pathology for improved prognosis.14 
 
o Congenital Heart Disease (CHD) – Haematological problems are 
common in cyanotic CHD and can affect the outcome of these patients. 
Erythrocyte numbers are regulated by factors that affect tissue 
oxygenation, that involve erythropoietin produced in the kidneys.30 The 
resultant activation of erythropoietin produces an increase in red blood 
cell mass, thereby increasing blood viscosity. Iron deficiency can also 
affect blood viscosity. This increase in blood viscosity increases the risk 
of DVT, PE and resultant CVA have been recorded.30 There are also 
documented cases where circulatory shunts in patients with cyanotic 
CHD involving venous blood bypassing the normal filtration action of 
the pulmonary system, have resulted in PEs which originally arose in the 
venous circulation, passing directly to the systemic vessels. These 
patients often have underlying polycythaemia and cyanosis.31 
 
o Lupus antibodies – Systemic Lupus Erythematosus (SLE) is a disease 
thought to be linked with immunological mechanisms of tissue injury 
with various clinical presentations and outcomes. It is typically found to 
have a number of antibodies to cellular nuclear components among 
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other.31 A sub-set of patients with Lupus are at increased risk for 
thrombosis or may develop a second antibody to prothrombin that could 
result in hypoprothrombinaemia resulting in haemorrhagic episodes.32 
 
1.3.2  Inherited risk factors 
o Sickle cell disease – This occurs in African, Indian, Caribbean, 
Mediterranean populations among others, which is characteristically 
represented by a genetic mutation of one of the haemoglobin molecules. 
Heterozygotes (sickle cell traits), 8 to 13% of African Americans are not 
anaemic, but have one abnormal gene (HbAS), whereas in homozygotes 
(sickle cell anaemia), approximately 0.3% of African Americans, both 
genes are abnormal (SS).32,33 Distorted and inflexible red blood cells 
obstruct the microvasculature which results ultimately in thrombosis and 
or infraction. This disease can produce a hypercoagulable state as part of 
the “sickle cell crises”, most likely as a result of abnormal platelet 
function, thrombin production, regulation and fibrinolysis.33 An increase 
has been found, in levels of markers of endothelial tissue activation 
including E-selectin, von Willebrand factor, and Interleukin 6 (IL-6), 
among others, which encourages thrombin production. Carriers of the 
sickle cell trait may also be predisposed to thrombosis.2,34 The 
percentage risk has not been documented thus far according to my 
literature research. 
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o Thalassaemia – Clotting is a well-known complication of 
Thalassaemia.2 This is a group of familial microcytic anaemias with 
typically impaired haemoglobin synthesis with resultant decreased 
haemoglobin. This disorder is particularly common in populations of 
Mediterranean, African as well as South East Asian origin and is one of 
the most commonly found genetic haematological disorders. Unbalanced 
haemoglobin synthesis is a result of impaired productions rates of one or 
more of the globin polypeptide chains (α, β, γ, δ).32 In particular, 
significant haemostatic changes have been found in patients with β-
Thalassaemia Major (β-TM) and β-Thalassaemia Intermedia (β-TI), as 
well as in α-Thalassaemia (Haemoglobin H Disease). Increased 
thrombotic events have been especially linked with β-TI from infancy, 
which is now acknowledged as a chronic thrombotic state linked to 
abnormalities in coagulation factor and inhibitor levels, as well as 
various alterations in fibrinolytic system factors.35 
 
There is chronic platelet activation in Thalassaemia which has been 
found after measuring the breakdown products of thromboxane A2 and 
prostacyclin (PGI2), in the urine.35 Increased levels of endothelial cell 
adhesion proteins found in the blood of Thalassaemic patients, has also 
been thought to be linked to the thrombotic complications of 
Thalassaemia, due to endothelial cell stimulation or injury.35 Monocyte 
and granulocyte cell activation, are also thought to be factors 
contributing to endothelial damage and thereby the thrombotic state 
found in Thalassaemia.35 Decreased levels of coagulation factor 
 14 
 
inhibitors such as protein C and protein S, have also been found in 
patients with β-Thalassaemia.35 
 
Decreased levels of heparin co-factor II are known to be another cause of 
the hypercoagulable state linked to Thalassaemia.35 There are also higher 
levels of thrombin-ATIII found in many patients (young and old), with 
β-TM.35 It has been suggested that the red blood cells in patients 
suffering from β-TM and β-TI have negatively charged phospholipids, 
which may contribute to a greater production of thrombin and thereby 
greater activation of platelets, which in turn would all increase the 
thrombotic state linked to Thalassaemia.35 Therefore, the continuous 
thrombin production and increased fibrinolysis are thought to be the 
main two mechanisms contributing to the hypercoagulable state of the 
Thalassaemic disorder.35 
 
o Activated Protein C Resistance (APC) – This has been linked with 20-
40% cases of DVT/PE.36 APC forms part of the anticoagulation system 
which operates by disabling through cleavage, factors V and VIII of the 
clotting cascade. When there is poor anticoagulant reaction to APC, this 
is called APC resistance and is attributed mostly to Factor V Leiden 
mutation (>95%).36 The latter ultimately by means of several 
mechanisms involving amino acid replacement, decreases Factor V 
destruction by APC. 36 
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o Protein C deficiency – Is a Vitamin K dependant protein which has 
been associated with abnormal clotting.32 APC which results from 
thrombin binding to a receptor on the endothelial cells 
(thrombomodulin), has protease enzymatic catalytic activity, which 
ultimately affects the clotting cascade.32 Therefore the finding of this 
deficiency increases the risk of general thrombosis by up to 10%.9-11 It 
has been found to be associated with 2-5% with patients of DVT.36 This 
has been linked with thrombotic incidences in patients as young as new 
borns.36 
 
o Protein S deficiency – This protein acts as a co-factor of Protein C. It is 
a Vitamin K dependant protein which has been associated with abnormal 
clotting (see details above).32 This deficiency has been linked with an 
increased clotting risk of up to 10%.9-11 It has been found to be linked 
with 5-6% of patients with DVT/PE.36 
 
o Antithrombin III (ATIII) deficiency – ATIII is the primary inhibitor of 
key clotting cascade enzymes: thrombin, factor Xa, and factor IXa.32 
This deficiency (heterozygotes only have been identified), can increase 
the risk of clotting in the younger population by 10%.18,32 This has been 
found to be linked with 2-4% of patients with DVT/PE.36 
 
o Factor V Leiden mutation – This is a very common congenital cause of 
PE as a result of altered response to APC producing impairment of the 
natural anticoagulation system.36 This is found in 5% of the average 
population and is a very common cause of PE and DVT.4,18 The presence 
of this factor increases the risk of venous thrombotic events 7 fold in 
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heterozygotes and 80 fold in homozygotes. The risk of thrombotic 
incidences is further increased in pregnancy (60% DVT/PE during 
pregnancy, especially second trimester or post-delivery), diabetes 
mellitus, any form of hormone therapy (oral contraception as well as 
long immobilisation due to various causes).36 Studies have documented 
up to 33% of families demonstrating inherited clotting disorders, having 
two genetic impairments, one of which being Factor V Leiden mutation. 
Many of these families have been found to have deficiencies of mainly 
Protein C, Protein S and or Antithrombin III (ATIII).36 (See Protein C, 
Protein S and ATIII above). 
 
o Other factor deficiencies – Other factors include, Dysfibrinogenaemia, 
Plasminogen deficiency, possibly others such as raised lipoprotein levels, 
elevated homocysteine, factors VIII, IX and XI, thrombin-activated 
fibrinolysis inhibitor.4 
 
1.4 Clinical presentation 
 
The clinical presentation of a PE is seldom the “typical” symptomatology of acute 
shortness of breath (SOB) with haemoptysis, pleuritic chest pain and tachycardia. 
Also a PE does not always present with a DVT.5,6,10 In fact, the majority of PEs 
present with atypical symptoms or as silent pathologies.1,5,37  
 
A PE may occur alone, or in combination with DVT in an estimated 70-80% of 
patients.3,4 In approximately 50% of the latter patients, there is a proximal DVT.3,4 
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About a 33% of the patients with PE may have an associated DVT that may have 
embolised at the time of diagnosis.3 Approximately 66% of PEs are only 
diagnosed post mortem,1,37 or about 40% may have no specific symptoms, but 
upon vague clinical presentation, a PE may be confirmed by an imaging 
technique.4,11,25  
 
The distribution of DVT has been found to be below the knee in 48% of cases, 
between the knee and inguinal ligament in 36% and above the inguinal ligament 
in 15%.38 Portal venous thrombosis associated with liver cirrhotic disease (6 – 
11%), is another form of venous thrombosis but is very uncommon.39 
 
A PE can present in the following manner: 
• Classic - As previously noted, the classic symptoms of a PE are acute SOB, 
haemoptysis, pleuritic chest pain with and without SOB. Also tachycardia and/ 
or increased respiratory rate (RR) may be clinically noted. Classically a DVT 
has embolised and caused a PE, however, this is in fewer than 20% of 
patients.5,6,40 
 
• Atypical - Vague scenarios such as nausea, vomiting or syncope,5,6,10 as well 
as abdominal pain, fever (<39°C, especially with pulmonary infarction),5,18 
convulsions, persisted cough, wheezing, new onset of atrial fibrillation, 
confusion and other, are some of the atypical clinical presentations of PE 
forming a group of about 25% to 35% of patients whose final diagnosis is 
PE.18,40  
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In the latter group, the following risk factors may be of benefit in diagnosing a 
PE, travelling four hours or more in the last month, smoking, central venous 
procedures within the last three months, heart failure, chronic obstructive 
airway disease, Irritable Bowel Syndrome (IBS) and varicose veins.18,23  
 
• Silent – Approximately 60% to 70% of patients with a final diagnosis of PE 
may be discovered accidentally when a patient presents with no significant 
symptoms or a vague symptom such as slow progressive SOB, followed by a 
sudden fatal collapse.18,40 The latter could be the result of an underlying 
massive PE, where the patient may be extremely haemodynamically unstable 
or even present in full cardiorespiratory arrest.4,5  
 
The presentation of patients with PE can be divided into four groups according 
to the amount and seriousness of the arterial occlusion. These are massive PE, 
acute pulmonary infarction, acute PE without infarction, and multiple PEs.18 
The physical manifestation of the four groups is as follows:6,10 
 
• Massive PE – these patients are usually shocked with increased Heart Rate 
(HR) and RR, low Blood Pressure (BP), poor peripheral perfusion and findings 
of pulmonary hypotension (see figure 1.2).6,10  
 
• Acute pulmonary infarction – this group may have palpable tenderness, a 
possible pleural rub and/or a decreased chest expansion and possibly signs of a 
pleural effusion.6,10 
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• Acute PE without infarction – this group may have increased HR and RR, 
pleuritic pain and/or crackles/wheezes may be found on occasion. There can be 
other physical signs and there is often a co-morbid disease happening.6,10 
 
• Multiple PEs – these patients may have pulmonary hypotension, signs of right 
sided heart failure, however, mostly non-specific signs that should alert the 
HCP to exclude a PE.6,10 
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The following four Chest Computer Tomographic Scan (CT Scan) images demonstrate a 
massive PE in a 37 year old female presenting with acute onset of dyspnoea: 
 
  
 
 
 
 
 
 
 
 
Figure 1.2 A series of four Chest CT Scan images demonstrating a massive PE in a 37 
year old female presenting with acute onset of dyspnoea. Permission granted from Drs 
Bloch and Partners Morningside MediClinic Radiology Department. 
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Due to the aforementioned variable presentations of a PE which makes the diagnosis of PE 
at times very difficult, a consensus came about, to use a standard set of clinical criteria in 
order to assist in diagnosing PE. It has been suggested that the use of the Wells Criteria in 
combination with the D-Dimer as a negative predictive tool, as well as the use of special 
investigations, also called confirmatory tests, is the best way of diagnosing or excluding a 
PE.11,41,42  
 
Two main clinical prediction rules have been used to assess the likelihood of the presence 
of a PE in various population groups, these being the Wells Score and the Geneva Score.42 
These scores have been found to confirm PE in around 10% of the low probability 
category, 30% in the moderate group and in 70% of the high probability group.42 In our 
study, all our positive PEs had a moderate probability Wells Score.  
 
In a review, Segal and colleagues, assessed fifteen studies in terms of the Wells Prediction 
Criteria.41 The highest pre-test probability group, was found to have DVT ranging from 
17% to 85%, the intermediate Wells Score probability group had a finding of 0% to 38% 
and those with the lowest probability score were found to have between 0% to 13% 
positive findings of DVT.41 Similar pre-test probability scores were done in another large 
group of patients (4693), the average age was 51 to 64 years with males being the 
majority.41 The positive PEs were found in 38% to 78% of patients with a high probability 
score in the intermediate probability score group, PEs were positive between 16% to 28% 
whereas in the low probability score group, PEs were positive only in 1% to 3% in this 
group.41 Therefore this review supports the use of a clinical prediction rule system in order 
to predict the likelihood of thrombotic disease in patients who are clinically suspected to 
have this.41  
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Siner and Foley also agreed that a low probability Wells Score with a negative D-Dimer 
result is both accurate and highly sensitive in the exclusion of patients suspected of having 
a PE, they also emphasised that clinical findings and judgement should be part of this 
workup for exclusion of PE.10  
 
Hugli and colleagues, looked at another set of criteria – The Pulmonary Embolism Rule-
out Criteria (PERC), to see the diagnostic efficiency and accuracy of it, as being able to 
either alone, or in combination with the revised Geneva score, exclude safely a PE in a 
patient.43 This study was a retrospective study like ours but, involved six EUs, and a very 
large study population (1675), compared to ours (189). The end results recommended that 
the PERC criteria, whether alone or used together with the revised Geneva Score, cannot 
safely exclude PE even in those patients who have a low risk probability score, especially 
in high risk populations.43 
 
Table 1.1 Wells Prediction Rule for Diagnosing Pulmonary Embolism 
Clinical Characteristic  Score  
Previous pulmonary embolism or deep vein thrombosis + 1.5 
Heart rate >100 beats per minute + 1.5 
Recent surgery or immobilization (within the last 30 d) + 1.5 
Clinical signs of deep vein thrombosis + 3 
Alternative diagnosis less likely than pulmonary embolism + 3 
Hemoptysis + 1 
Cancer (treated within the last 6 mo) + 1 
 
Wells Prediction Rule for Diagnosing Pulmonary Embolism: Clinical Evaluation Table for 
Predicting Pre-test Probability of Pulmonary Embolism 
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Note: Clinical probability of pulmonary embolism: low 0–1; intermediate 2–6; high >7  
Reprinted from Am J Med, Vol 113, Chagnon I, Bounameaux H, Aujesky D, et al, 
Comparison of two clinical prediction rules and implicit assessment among patients with 
suspected pulmonary embolism, pp 269-75, Copyright 2002. Kamangar N, McDonneli 
MS, Sharma S. Pulmonary Embolism. Table reprinted with permission from 
eMedicine.com, 2010. Available at: 
http://emedicine.medscape.com/article.com/article/300901. Updated Jan 14, 2010;1-47.18 
Table 1.2 The Revised Geneva Score 
Risk Factors  Points  
Age older than 65 y 1 
Previous DVT or PE 3 
Surgery (under general anesthesia) or fracture (of the lower limbs) within 1 month 2 
Active malignant condition (solid or hematologic, currently active or considered cured <1 y) 2 
Symptoms  
Unilateral lower limb pain 3 
Hemoptysis 2 
Clinical Signs  
Heart rate 75–94 beats/min 3 
Heart rate ≥95 beats/min 5 
Pain on lower limb deep venous palpation and unilateral edema 4 
Clinical Probability  
Low 0–3 
total 
Intermediate 4–10 
total 
High ≥11 
total 
 
The Revised Geneva Score* 
*Adapted from Prediction of pulmonary embolism in the emergency department: the 
revised Geneva score. Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, 
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Bounameaux H, Perrier A. Ann Intern Med. 2006 Feb 7;144(3):165-71. Kamangar N, 
McDonneli MS, Sharma S. Pulmonary Embolism. Table reprinted with permission from 
eMedicine.com, 2010. Available at: 
http://emedicine.medscape.com/article.com/article/300901. Updated Jan 14, 2010;1-47.18 
 
1.5 Diagnostic options leading to confirmation of diagnosis  
 
Since the 1990’s many imaging and laboratory tests have been assessed for their 
possible accuracy in confirming a PE/DVT, but the scientific evidence has been 
poor as to their reliability since no single confirmatory test or clinical discovery, 
has been found to be sensitive or adequately specific enough.4,9,10  
 
The HCP must start with a patient’s medical history, including noting any risk 
factors for PE, followed by a clinical examination of the patient suspected of 
having a PE as long as the patient is haemodynamically stable.10,44,45 
 
Diagnostic modalities may also assist in exclusion of other pathologies which are 
part of the large differential of PE.18 After the clinical examination, the following 
diagnostic modalities have been used alone or in conjunction with the clinical 
assessment:3,44,45 
 
• Chest X-ray (CXR) - These are often non-specific and limited in value unless 
an infrequent finding such as oligaemia or Hampton’s Hump is found on the 
CXR.18,40 The CXR findings are often normal or in the case of extensive PEs, 
can comprise of the following: a Westermark sign, pleural effusion, raised 
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hemidiaphragm and atelectasis.18 Alternate diagnoses such as pneumonia and 
CCF may be confirmed with a CXR, and may also be present together with a 
PE.40 
 
• Electrocardiogram (ECG)/Echocardiography (ECHO) – These both have a 
limited role in the assessment of PE and are used primarily to confirm other 
diagnoses such as pericarditis or AMI. The classic “text book” finding on ECG 
of S1Q3T3 is rarely found and can be found in the presence of many other 
conditions.3,6 More commonly a finding of tachycardia with or without 
inverted T-waves in the precordial leads is present.40 Other ECG signs 
observed in the presence of especially larger PEs include right heart strain, 
acute cor-pulmonale, right bundle branch block and right axis deviation.3,6 The 
latter ECG findings are only found in approximately a fifth of patients with 
documented PEs.3,6 
 
• Arterial Blood Gas (ABG) – This is an invasive and painful test for the 
patient. It has low sensitivity and specificity and therefore, also has a limited 
role in diagnosing PE, but rather assists in confirming the severity of other 
alternative diagnoses.40 
 
• D-Dimer – This is a non-invasive and fairly easy method used to exclude 
thrombotic disease. It is a fairly nonspecific test due to “false positives” that 
can result from other causes such as infection, in postoperative patients, 
injuries and other.40 Other studies have shown that the D-Dimer value is 
directly related to the size of a PE and has a fairly accurate prognostic 
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value.3,5,45 The D-Dimer assay is thought to have a fairly reliable negative 
predictive value and therefore, when it has a negative value, can almost always 
be used to exclude the diagnosis of PE.40 This test detects the fibrin end 
product after fibrinogen is degraded.11,14,46 The latter is quantified by several 
assays available, measuring this fibrinolytic activity of plasmin in the 
circulation.44 
 
• Pulmonary Angiography – This diagnostic modality has been thought to be 
the “gold standard” for diagnosing PE. However, it is invasive, costly, uses 
intravenous contrast that may cause renal toxicity, allergic reactions and other 
complications, is a lengthy procedure and not available at all medical 
facilities.40 
 
• VQ Scan – This is done in two stages, one stage involving ventilation and the 
other perfusion. Radioactively labelled agents are injected intravenously as 
well as inhaled in order to demarcate the areas of the lungs that are being 
perfused as well as ventilated. Here an abnormality such as compromised areas 
of ventilation or areas without sufficient circulation will alert the investigator 
to the probability of a PE. The shortcomings of this modality involve patients 
with possible pre-existing pulmonary pathology that will give rise to abnormal 
VQ Scans with or without current acute mismatch. There is also the need to 
consider pre-test probability scores in these patients that can also help increase 
the diagnostic accuracy of this scan.40 
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• CT Chest - The Spiral CT is frequently used as it is less complicated, less 
“operator dependant”, non-invasive, more rapid and more available than 
pulmonary angiography.40 It is also less expensive and fairly accurate 
diagnostically, compared to the VQ Scan, Magnetic Resonance Angiography 
(MRI) Scan and pulmonary angiography, whilst confirming other pathologies 
that may be present, such as infection or tumours. Unfortunately the Spiral CT 
also uses contrast that can affect kidney function or cause other 
complications.40 It is 85% reliable and if positive, there is no need for further 
confirmatory investigations.14,47,48 
 
• Other – Other modalities such as the MRI, cardiac biomarkers, such as cardiac 
Troponin levels, can be markedly raised especially with the larger PEs.18 
 
Alveolar dead space evaluations may become a future diagnostic measure to be 
implemented with other modalities to exclude PE. Alveolar dead space is an 
abnormal finding, occurring when the alveoli are ventilated but are not 
receiving circulation due to obstruction caused by the PE.40 
 
 
In pregnant patients, the role of D-Dimer assays in diagnosing thrombotic disease is still 
being debated. A recent review article by Durán-Mendicuti and Sodickson, points out that 
a different approach is therefore warranted in this population group, based on clinical 
suspicion and history, involving the use of CXR and doppler/Ultrasound of extremities.49 
The CT Pulmonary Angiography (CTPA), although being highly sensitive and specific, 
also involves contrast media and is higher in radiation than a VQ Scan. This is an 
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acceptable alternative radiological confirmatory investigation especially if there is 
contraindication to the CTPA.49 The decision will depend on local protocols, resources and 
availability of the various imaging modalities as well as specialist cover and specific 
medical history of the patient, for example, allergies to contrast media.49  
 
A study done by Kline and colleagues in an EU, looked at the use of exhaled CO2 in 
detecting a segmental/subsegmental PE in moderate risk patients, based on the assumption 
that a PE decreases the ratio of exhaled End-Tidal CO2/O2.50 The study was conducted on 
495 patients. The D-Dimer measurement was taken into account and the conclusion was 
that in moderate risk stratified patients, who had a positive D-Dimer and an End-Tidal 
CO2/O2 ratio <0.28, the presence of a segmental or subsegmental PE was strongly 
suggested, while an End-Tidal CO2/O2 ratio >0.45 inferred the absence of such a PE as 
would be confirmed on CT angiography.50 
 
There has also been a suggestion to combine spiral CT (angiography) with CT venography 
in order to increase the sensitivity of the spiral CT outcome to 90%.18  
 
Over the last twenty years, a spiral CT of the chest has become the procedure of 
radiological investigative choice for the diagnosis of PE.42,51 CT Scan results need to be 
used with the pre-test probability in mind.52 
 
A Spiral CT cannot be used in patients with pre-existing renal pathology as it can cause 
nephropathy. In the latter case, a VQ Scan can be used instead of a Spiral CT.5 A VQ Scan 
used to be the main radiological study, prior to the Spiral CT and were also useful when 
CT Scans were not available or contraindicated, for example if a patient is allergic to the 
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intravenous contrast.11,52 If the VQ Scan cannot be clearly interpreted, a CT angiogram 
should be performed.11 The CT Scan of the chest should be used together with clinical 
probability D-Dimer blood assay with or without lower limb dopplers, in order to confirm 
or exclude thrombotic disease, instead of using one of these tests on its own, which is not 
thought to be accurate in confirming DVT/PE.5,19  
 
In a study performed by Pesavento and colleagues, the value of a 64-detector row CT in 
confirming a PE in suspected patients, was assessed in a recently conducted study 
(2011).53 They concluded that the 64-detector row CT is a very efficient radiological 
investigation which can potentially rule out with no hesitation, the presence of a PE in 
suspected patient populations.53 
 
In a study performed by Kluge and colleagues, involving 221 patients suspected of having 
an acute PE, a multi-technique thoracic MRI Scan of the lungs was used in combination 
with MRI venography. The two latter investigations together confirmed a final diagnosis 
of PE in this group of patients.3,54  
 
Certain biomarkers such as blood Troponin levels, have been found to help in the 
exclusion of PE. This biomarker is not sensitive when used alone but, can be used as part 
of risk assessment in patients with a known PE.3 Blood Troponin levels have been found to 
be raised in as many as 50% of patients with moderate to large PEs and this is thought to 
be due to sudden right ventricular muscle stretch.55 There is also an associated mortality 
predictive value, where studies have documented an association with worse outcome when 
raised Troponin levels are found in the presence of a PE, but more research is necessary.56 
 30 
 
Another biomarker is the Brain-type Natriuretic Peptide (BNP) which increases in CCF 
and other conditions that cause pulmonary hypotension, due to the ventricle enlarging.3,57 
 
A study performed by Fedullo and Tapson, highlights the ECHO and biochemistry such as 
Troponin levels and/or BNP levels as helpful in evaluating the right ventricle function.5 
They are not diagnostic of a PE but, can help with assessment of prognostic outcome as 
one of the fatal complications of PE involves systemic hypotension as a result of right 
ventricular impairment. It was suggested in this article that repeating blood tests which are 
similar to the latter blood tests, could be done after therapeutic intervention, but this is not 
yet a definite practise protocol.5  
 
There has been an on-going debate regarding the best approach that should be used to 
diagnose and manage a patient with an acute PE, two articles in 2011 dealt with this.58,59 
The one written up by Stein and colleagues was a survey of various “investigators” who 
looked at the current approach to the diagnosis of an acute PE and noted that VQ Scans or 
Perfusion Scans on their own, as well as Single Photon Emission CT (SPECT) VQ Scan, 
are among the common radiological investigations of choice due to the on-going 
awareness of the hazards of radiation.60 However, the patient’s sex, age and plain CXR had 
a bearing on these decisions.58 Sheares in her article discussed the importance of specific 
hospitals having individualised strategies for assessment of patients with suspected PE.59 
This would involve early risk assessment as well as a specific D-Dimer assay and a scoring 
system for pre-test probability assessment, which in combination would help select those 
requiring further radiological investigations.59 These models according to the author, 
should take into account the local specialist availability and resources among other 
variables.59 
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The use of the CT Chest is highlighted in Figure 1.3, by the two normal Chest CT Scan 
images of an 82 year old male. The CT Chest was one of the investigations of choice to 
exclude a PE in this elderly patient. 
 
 
 
 
 
Figure 1.3 Chest CT Scan images demonstrating a normal chest pathology in an 82 year 
old male. Permission granted from Drs Bloch and Partners Morningside MediClinic 
Radiology Department. 
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In our private EU, best practise depends on the resources of the patient (medical aid or 
private paying patients). Generally our practise involves diagnosis or exclusion of PE 
based on clinical examination, ECG, Wells Criteria, D-Dimer, Spiral CT of the chest, or a 
VQ Scan in the case of a pregnant patient. 
 
1.6 Diagnosis of PE in private and state facilities 
 
The incidence of PE has been increasing in the EU with atypical clinical 
presentations becoming more frequent and therefore a greater resultant morbidity 
and mortality due to the subtlety of many of these presentations.3,61 Therefore, an 
HCP cannot rely on the clinical examination and history to accurately diagnose or 
exclude a PE. In fact, the PE has been referred to as the “great trickster” for this 
reason.3 The size of the PE may affect the way in which a patient presents to the 
EU.3,5,45 
 
The confirmation of a PE once a D-Dimer is positive should follow with a Spiral 
CT of the chest or a VQ Scan if the former is not available.15,47,62 Pulmonary 
angiography used to be the gold standard for diagnosis of a PE.11,46 It requires 
expertise and is an invasive procedure with possible complications such as 
respiratory and renal failure. Therefore this conventional diagnostic method is not 
commonly used these days, if the former modalities are available.14,63,64 
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1.7 Review of literature on audits done in private and public EUs 
 
Diagnostic usefulness of this test has been evaluated in various hospital and EU 
settings (public and private) in other countries but not in South Africa or in our 
private hospital EU.55,65,66 Results of this study will inform private hospital EU 
“best practice”. 
 
There is very little literature pertaining to the usefulness of the D-Dimer test 
within private EU worldwide. In South Africa, there are no other studies that have 
been written up documenting an audit of the usefulness of the D-Dimer test in the 
diagnosis of PE in a private EU. There is also no literature to date of the latter 
pertaining to the public sector in Johannesburg, South Africa.  
 
 
2.0 THE D-DIMER TEST 
 
2.1 What is the D-Dimer and how is it generated? 
 
The D-Dimer is commonly used in our EU, as in other EUs in other countries, to 
exclude a number of sinister medical conditions, the leader being the PE, in 
suspected patients.5,44  
 
The D-Dimer is a measure of the breakdown product of cross-linked fibrin,5,67 
which is found in the blood and used to detect and/or quantify the degree of fibrin 
formed, in order to monitor the change or development of various clinical 
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pathologies. This fibrin formation can also be used to ascertain the effectiveness 
of a therapeutic course being given to a patient to treat a thrombotic disorder.4,5,45 
This test should always be interpreted with the patient’s history and clinical 
findings in mind and never viewed in isolation.48 
 
An HCP would use D-Dimer levels as a screening test commonly in certain 
scenarios. These would include where the patients present with possible 
thrombotic disease or if thrombo-embolic disease is clinically suspected.48,63,68 
Other scenarios include the diagnosis and monitoring of the coagulation activity 
in DIC, detection of recurrent thrombo-embolic disease or the risk stratification of 
the latter patients.45,68 It has also been suggested that the D-Dimer may be a 
possible future biomarker that could play a very important role in diagnosis and 
prognostic outcome of AAA, as well as in severely atherosclerotic patients and 
patients with clinically localised prostatic cancer.69-71 There have been other 
recent studies showing the possible significance of the D-Dimer assay in the 
detection of “silent” phlebothrombosis.72 
 
The D-Dimer can also be used as a predictor of mortality in patients with PE, 
since raised D-Dimer levels have been associated with death.42 There has been a 
direct correlation between the level of the D-Dimer and the severity of illness, 
radiological degree of the illness as well as the mortality outcome (in hospital).73 
Also in the literature, there is much emphasis on how the knowledge of the D-
Dimer results affects the clinical probability score for PE. Hence, the clinical 
assessment of the patient is very important prior to obtaining the D-Dimer assay 
result.68  
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A negative D-Dimer is thought to rule out a PE and DVT with low clinical 
probability, with relatively greater certainty.11,41,74 There is a debate whether D-
Dimer testing alone, is accurate enough to confirm or exclude a PE.11,15  
 
It has been suggested that patients whose D-Dimer falls between 200 and 
500ng/ml have very low risk stratification and thereby may not need any other 
radiological or other investigations.75  
 
Another study supported that the accuracy and specificity of the D-Dimer test 
decreases as time increases from the time of onset of initial symptoms in a patient 
with suspected PE/DVT, especially after three days from the time of onset of 
symptoms in elderly patients. No actual age range for these patients is 
documented in this review.41,76 
 
The use of the quantitative ELISA D-Dimer assay has been looked at in literature 
as the assay of choice for patients suspected clinically to have a PE, however, it 
has been suggested that it be made less expensive and be designed to be faster in 
its turnaround time so that this test can be used efficiently to screen these 
patients.64 
 
The D-Dimer is commonly used in our EU at the Morningside Private MediClinic 
to exclude conditions, especially PE. 
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2.2 The principles of D-Dimer test 
 
The different principles of assays available for D-Dimer testing are: 67 
 
o Whole blood/Latex agglutination 
o Enzyme-linked immunosorbent/Monoclonal antibodies 
o Turbidimetric 
o Immunofiltration 
 
 
 
 
Figure 2.1 Principles of D-Dimer testing 
D-Dimer. Available from: URL: http://en.wikipedia.org/wiki/D-Dimer67 
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2.3 D-Dimer tests and different methodologies available 
 
o Whole blood/Latex agglutination (for example, commercially available 
Semi-quantitative Latex Agglutination and manual Whole-blood 
Agglutination)11,14 
 
These tests do not require complicated advanced equipment, and allow fast 
clinical decision making. They are less sensitive methods and therefore cannot 
detect low levels of D-Dimer antigen but, are specific enough for the exclusion 
of PE and DVT.14 
 
This is a qualitative red cell agglutination (whole blood) technique, with a 
sensitivity of 84.8% and a specificity of 68.4% as found in a patient trial,77 and 
is therefore commonly used for the diagnosis and exclusion of PE. It is a fast 
technique that has been noted by the British Thoracic Society (BTS) among 
others, to be used safely in conjunction with Wells Criteria showing a low pre-
test probability score in exclusion of a PE in low risk patients.78 
 
This assay depends on visually detecting the flocculation of latex particles, and 
therefore there is a strong component of operator subjectivity. The latter may 
be one of the reasons for this qualitative latex fixation D-Dimer assay being 
noted to be less sensitive for PE detection in published studies.79 
 
The principle of this assay involves using two monoclonal antibodies against 
fibrin breakdown products, which contain the D-Dimer structure element.12 
 38 
 
One of the antibodies is gold labelled, and the other antibody is bound to 
biotin.12 These two antibodies bind to the D-Dimer and form a sandwich like 
entity.12 Once the red blood cells have been removed from the blood sample 
collected, the plasma passes through the detection area where the gold labelled 
D-Dimer entities bind, showing up as a red (“signal”) line.12 Unbound gold 
tagged antibodies will attach to the control “line”, validating the specific assay. 
The colour of the signal line will intensify in direct proportion with the amount 
of the D-Dimer concentration found in the plasma and will be shown as a 
quantitative result.12 
 
Computerised methods that quantitate latex agglutination rates, have also been 
found to have excellent sensitivity and correlate well with Enzyme-linked 
Immunosorbent Assay (ELISA).14 ELISA and latex quantifying assays, have 
both been approved by the American Food and Drug Administration, for the 
exclusion of PE and DVT and are being used internationally.14 
 
When comparing the tests, the ELISA, ELISA and Fluorescence Assay 
(ELFA), the micro-plate ELISA and the automotive quantitative measuring 
assays are much more sensitive than the whole blood agglutination assay, but 
have lower specificity. Therefore, further diagnostic imaging would be 
necessary to confirm the diagnosis of a PE and/or DVT when ELISA based 
methods are used.14,80 The whole blood agglutination assays have a higher 
negative predictive value, in populations with lower risk factors.14,80 
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Latex agglutination assays depend on the availability of a sufficient amount of 
D-Dimer antigen that would be present on fibrin degradation products. This 
would determine whether agglutination will be initiated. This assay, is run in 
plasma and detects D-Dimer antigen once fibrin has cross-linked with the 
assistance of factor XIIIa.14 
 
The latter assay has shown poor correlation with the diagnosis of PE, therefore 
is notoriously unreliable but, often used in diagnosing haematological 
conditions such as DIC.6 Sensitivity has been found to be between 50-70% and 
specificity slightly higher at 76%, which is thus a limitation as far as its use in 
diagnosing PE.6,11 
 
o Enzyme-linked immunosorbent/Monoclonal antibodies (for example, 
Microplate ELISA and ELFA) 11,14 
The ELISA methods were initially developed for the purpose of research, 
before latex agglutination assays, and they relied on antibody binding to the D-
Dimer antigen, after the marking of the antigen with an antibody detection 
system. The latter assay was extremely sensitive, especially when compared to 
the latex agglutination test,6 but was more time consuming and technically not 
easily performed.14 
 
The ELISA based assays have a high sensitivity of 97%, but specificity can be 
as low as 8%.6,81,82 They can detect elevated D-Dimer antigen associated with 
various pathologies, making this a nonspecific marker, as a positive result may 
also be present in sepsis, neoplasm, trauma and other injury states.6,14,83 These 
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assays can take several hours to run.81 A negative result can assist in excluding 
a PE in low and moderate probability Wells scoring groups.84 
 
Computerised latex agglutination assays, record the rate that different antibody 
coated particles combine with available D-Dimer antigen. These assays require 
specialised, computerised machines.14 The specificity of these antibodies, are 
not the same and they may react differently with high and low molecular 
weight fibrin breakdown products.14 Each assay is known to have a specific 
sensitivity to different size breakdown products.14  
 
o Turbidimetric (for example, Second-generation latex agglutination -
immunoturbidimetric)11,14 
These assays use spectrophotometry to detect the rate of precipitation of latex 
particles which are coated with antibody to the D-Dimer peptide.79 This 
method involves a plasma sample which when placed in a cuvette containing 
latex particles, the particles will start to adhere to each other. As they combine, 
this will affect the amount of light detected across the cuvette which is directly 
proportional to the amount of D-Dimer present in the blood plasma.79 
 
The immunoturbidometric assays have shown a sensitivity of greater than 
95%, but nonspecific for detecting PE in the EU and take long to run. They 
have been likened in their methodology to the ELISA method.79,82 
 
o Immunofiltration (for example, Immunofiltration and sandwich-type 
assays)11,14 
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These are assays involving fluorescent end point detection. They use light 
microscopy with a fluorescence microscope. The method engages specific 
antibodies to targeted antigens aimed at fluorescent dyes binding to specific 
cellular molecules, which will ultimately allow the visualisation by the 
fluorescent microscope.85 These cellular structures which have been tagged 
with the fluorescent dye, will be seen lit up as opposed to a black 
background.86 This technique maybe problematic due to “photobleaching” 
which can cause less activity, hence falsifying the ultimate D-Dimer result.85 
 
They are equally as sensitive as they are specific. They are faster with a wider 
linear range that could detect D-Dimer levels between 0 and 1000µg/ml, 
making them new and promising in efficacy, with shortened lab turnaround 
times and excellent sensitivity of 97-99% and 97-99% specificity.14,82 These 
assays also have exceptional negative and positive predictive values as 
opposed with the gold standard ELISA.14,87 
 
A newer D-Dimer assay by the name of “Tina-quant”, has been evaluated in a 
study performed by Sanchez and his colleagues published in 2011.88 The 
authors looked at this assay’s diagnostic accuracy as compared to the VIDAS 
D-Dimer assay (an automated system that uses the enzyme-linked fluorescent 
assay method).88,89 This was a retrospective study conducted on patients who 
had D-Dimer assays done at an EU over six months before and after the 
change to the new “Tina-quant” assay.88 The authors concluded that the new 
D-Dimer assay was more effective in terms of reducing a patient’s transit time 
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through the EU as well as reducing the number of unnecessary radiological 
investigations.88  
 
2.4 Causes of raised D-Dimer 
 
A positive or high D-Dimer suggests increased clotting and fibrinolysis, 
prompting further investigations to reach a definitive diagnosis.3,41 It is not 
conclusive in diagnosing a PE and maybe non-specific and positive in different 
situations, requiring a Spiral Computed Tomography Scan (CT) of the chest or a 
VQ Scan for final confirmation.3,45,46 
 
The D-Dimer can be fairly non-specific and may be positive in a number of 
different situations besides PE and DVT, including Acute Coronary Syndromes 
(ACS), pregnancy, Chronic Renal Failure (CRF),73,90 sepsis, malignancy, various 
anaemia’s including sickle cell disease, leukaemia, pregnancy, and other 
inflammatory/pyrexial disorders, as well as post operatively.11,19,44 The elderly 
and hospitalised patients may also have increased D-Dimers.41 D-Dimers can also 
be raised for a time period as long as six months post therapeutic course for a 
previous DVT.6,45,62 There have also been suggestions in the literature that 
repeated D-Dimer assays, post-anticoagulation therapy, can help plan the length 
of management of the specific patient being treated for a thrombotic episode, 
when this is their first episode.32  
 
With ACS, the D-Dimer value is used in combination with cardiac Troponin I 
(cTnI) to assess risk of the patient immediately and six hours post-admission, and 
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believed to be fairly accurate in early exclusion, rather than early recognition of 
those patients with possible cardiac pathology presenting with atypical chest 
pain.90 
 
Pneumonia (especially Community Acquired Pneumonia (CAP)), is thought to be 
one of those disorders that increase D-Dimer levels, due to activation of the 
fibrinolytic system (clotting cascades) within the alveoli, by means of endotoxins 
released by Gram-negative micro-organisms that are responsible for the 
pneumonia.73 In other words, a direct relationship (the D-Dimer increases with the 
severity of the disease) has been suggested between the raised D-Dimer found in 
various disorders and coagulation within or outside vessels during acute and 
chronic injury to the lungs.73 
 
Pelvic Inflammatory Disease (PID) is another example of a condition where the 
D-Dimer plays a very important role in indicating the severity of this disease.91  
This may have major implications pertaining to therapeutic options and success, 
as well as effects on the fertility of the concerned patient, but needs further 
investigation.91 The latter study which looked at PID, also was a retrospective 
analysis. The data obtained definitely showed an increase of D-Dimer in PID and 
is being suggested as being more sensitive than a C-Reactive Protein (CRP) blood 
test in terms of assessing severity of PID, although this article suggests that more 
studies are necessary to confirm this fact.91 
 
African American males with hypertension have been found in clinical studies to 
have raised D-Dimer levels compared to non-hypertensive African Americans.92 
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The same study also found high D-Dimer levels with increase in age. D-Dimer 
levels have been found to be raised with cardiovascular pathology as well as 
higher than in the non-Hispanic Caucasians. This was age independent.92 
 
Recent studies are looking at the D-Dimer as a potentially, very significant 
biomarker used for prognostic and diagnostic purposes, in patients with 
Abdominal Aortic Aneurysm (AAA).69 
 
Literature notes that the sensitivity of D-Dimer is very high, however, the 
specificity is much lower.14,64,74 The D-Dimer concentrations are known to rise 
with a patients’ age, with the specificity of the latter test declining with increasing 
age.55 This appears to make this test less effective with excluding a PE in these 
older patients.55,93 A suggestion has been made to increase the D-Dimer test range 
results, thereby improving the test specificity.55,94 This age corrected D-Dimer 
range, together with a clinical risk assessment, should aide the usefulness of the 
D-Dimer test with excluding PEs amidst older patients. The exact range requires 
further clinical studies.55 
 
2.5 Interpretation and performance characteristics of D-Dimer test  
 
There are different assays being performed which are of different sensitivity and 
specificity ranging from 80-100%.41,62,95 
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The D-Dimer test has a high negative predictive value used primarily to confirm 
or exclude possible thrombo-embolic disease.11,13,96 In EU practice, this test is 
often done not only for suspected PE, but also to rule out atypical PE.2,66,96 
 
An untreated or undetected PE may be associated with high morbidity and 
mortality, which can be minimised by a high index of suspicion on part of the 
HCP.10,64,94 This should prompt the HCP to investigate further by means of the D-
Dimer testing with or without the follow up appropriate imaging, depending on 
the patient’s risk factors and clinical findings.2,4,5 
 
2.6 Limitations of the D-Dimer test 
 
Limitations of the D-Dimer test, include it being a nonspecific test which may be 
imprecise and inaccurate despite strict operational and technical attempts at 
quality control.55,74,97 This can arise from many factors including various drugs 
that have been possibly taken by the patient even though in therapeutic doses. The 
presence of rheumatoid factors can also affect the validity of the D-Dimer 
test.4,5,41 
 
Recent research suggests that the timing of the D-Dimer assay, relative to the 
onset of symptoms might have an impact on the final diagnosis, especially if the 
assay is done a week later, this could decrease the value of the D-Dimer in risk 
stratification of the patient suspected of DVT or PE.76 Most modalities are less 
reliable than the D-Dimer test, according to the literature.11,14,37 
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The D-Dimer can be an expense to the patient which is another reason for its role 
to be justified or negated.11,45,62 However, it is still cheaper and more rapid than 
other confirmatory investigations, such as the CT, and can be used as a screening 
test in the EU.65,74,97 
 
Other factors such as raised D-Dimer levels (>50µg/ml), high concentrations of 
the D-Dimer fragments that occur as a result of thrombolysis and the presence of 
lipoic acid, may result in incorrect lower values of the D-Dimer test.3,14,74 
 
The D-Dimer assays may be limited in both specificity and sensitivity,41,44,45 
where in some literature, sensitivity of the D-Dimer test has been documented to 
be mostly very high, and the specificity has been noted to be much lower.14,64,74 
 
The experience of the lab technician reading the results, is of the utmost 
importance in order to identify a weak positive result.62 
 
 
3.0 STUDY OBJECTIVES 
 
This study was a clinical audit which aimed to establish the usefulness of the D-Dimer 
test in the diagnosis of PE in an EU of the Morningside Private MediClinic (MMC) in 
Johannesburg. 
 
The specific objectives were to:  
• Get results of all D-Dimer tests performed (the D-Dimer test and other tests are part 
of routine diagnosis of PE in our EU setting). 
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• Establish the proportion of those who had a D-Dimer test as part of their diagnostic 
test for PE  
• Identify patients presenting with non-specific clinical features of PE in the EU  
• Establish PE confirmatory tests performed on the identified patients  
• Correlate the D-Dimer test results with clinical features and confirmatory tests 
• Summarise the usefulness of the D-Dimer test in this study population. 
 
The idea of this research project is to find out statistically how valuable the D-Dimer 
investigation is in confirming the presence of a PE, and therefore the following was 
tabulated: 
 
o D-Dimer vs PE, positive and negative predictive value, sensitivity and 
specificity of the D-Dimer in diagnosing PE 
o D-Dimer vs Wells Criteria, positive and negative predictive value, sensitivity 
and specificity of the D-Dimer in diagnosing PE 
o D-Dimer vs CT Chest, positive and negative predictive value, sensitivity and 
specificity of the D-Dimer in diagnosing PE. 
 
 
4.0 MATERIALS AND METHODS 
4.1 Ethics approval 
This study was approved by the University of  the Witwatersrand Human 
Research Ethics Committee, Clearance Certificate number: M090659. (See 
Appendix A). 
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4.2 Study Population 
Inclusion Criteria  
o Patients at the MMC EU with D-Dimer test done. 
o Adults over 18 years of age or older 
o Both male and female 
 
Exclusion Criteria  
o Patients <18 years old  
o Patients with trauma  
o Patients with other causes of raised D-Dimers such as a) ACS b) pregnancy c) 
sepsis d) malignancy e) anaemias f) pyrexial disorders g) post-operative 
patients h) elderly i) hospitalised patients j) patients less than or equal to six 
months post therapy for previous DVT/post thrombolytic therapy k) renal 
dysfunction as measured by raised plasma creatinine above the upper limit of 
normal. 
 
4.3 Study design 
This was a retrospective, cross-sectional uncontrolled study. 
 
4.4 Review of records 
After approval by the University of the Witwatersrand Human Research Ethics 
Committee and the management of the Morningside Private MediClinic EU, a 
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clinical audit of records was done at the Morningside Private MediClinic EU from 
1st March to 1st June, 2009.  
 
4.5 Collation of other tests done 
The confirmatory tests were tabulated according to whether they were “done” or 
“not done”, as well as if done, whether they were negative (neg) or positive (pos). 
(Table 5.4). 
 
4.6 Analysis of data 
A data collection sheet was used (see Appendix A). 
 
4.7 Calculation of Wells Score 
The Wells Score was calculated according to the Wells Criteria. (Table 1.1). 
 
4.8 Analysis of results by statistical tools 
Extracted data included demographics, diagnoses and confirmatory tests done. 
Continuous and categorical variables of data collected were summarized using the 
Stastistica 9.0 package.  
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5.0 RESULTS 
 
5.1 Data Analysis 
 
The results are presented in Tables 5.1 – 5.7. A data base of 189 (= N) of 3948 
patients (5%) seen at MMC EU had D-Dimers measured, over the data collection 
period (1st March to 1st June, 2009).  
 
Table 5.1 depicts the demographics of the study population used. Out of the 189 
patients 93 were females and 96 were males. There were various categories of 
diagnoses, of the total 189 (N) patients 6(3%) had AMI, 13(7%) Anxiety, 6(3%) 
Arrhythmia, 5(3%) CVA, 9(5%) Chest Infection, 42(22%) Chest Pain, 19(10%) 
GORD, 7(4%) Headache, 8(4%) Hypertension, 55(29%) Other, 5(3%) PE and 
14(7%) Syncope. The next demographic was age. In the various categories of 
diagnoses of the total 189 (N) patients, the following were the ages in years with 
the ranges being in brackets: 59(37-73) AMI, 31(19-45) Anxiety, 68(24-89) 
Arrhythmia, 59(39-75) CVA, 54(23-86) Chest Infection, 44(21-86) Chest Pain, 
41(22-77) GORD, 42(23-67) Headache, 58(42-87) Hypertension,46(18-88) Other, 
57(38-84) PE and 42(22-87) Syncope. (Table 5.1) 
 
Gender wise, a greater percentage of females predominated in the following 
categories: Arrhythmia (67%), Syncope (71%), PE (60%), GORD (63%), 
Headache (57%), Anxiety (54%), Chest Infection (56%), the latter is supported by 
literature.19 A minor percentage of females presented with AMI (33%), CVA 
(20%), Chest Pain (43%), Hypertension (50%), and Other (42%). (Table 5.1).  
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 Out of 189 D-Dimers taken, there were 40 (21.16%) which were positive for a 
number of conditions including PE (Table 5.3). The highest positive D-Dimers 
within the specific categories, were recorded for PE, 5 positive D-Dimers out of 5 
patients within this category equalled 100%, Chest Infections which were 5 out of 
9 patients equalled 56%, Acute Myocardial Infarction (AMI) which is 2 out of 6 
patients equalled 33%, Arrhythmia which is 2 out of 6 patients equalled 33%, 
Hypertension which is 2 out of 8 patients equalled 25%, Chest Pain which is 6 out 
of 42 patients equalled 14%, Anxiety which is 3 out of 13 patients equalled 23%, 
Headache which is 1 out of 7 patients equalled 14%, Syncope which is 1 out of 14 
patients equalled 7% and Other which is 13 out of 55 patients equalled 24% 
(Table 5.1 and 5.3). We note here, that the group of Other, constitutes 32.5% of 
those positive for D-Dimer, whereas, AMI forms 5% of this total group, Anxiety 
7.5%, Arrhythmia 5%, Chest Infection 12.5%, Chest Pain 15%, Headache 2.5%, 
Hypertension 5%, PE 12.5% and Syncope 2.5% of the positive D-Dimer group. 
Patients with the diagnosis of CVA and Gastro-oesophogeal Reflux Disease 
(GORD) had no positive D-Dimer results, hence were not listed in Table 5.3.  
The group of Other, appears to be the largest group of positive D-Dimers, within 
the positive D-Dimer group (32.5%). This group includes patients with diagnosis 
such as Oesophageal Spasm, Muscle Strain Back, Unknown diagnosis, TB, Upper 
Respiratory Tract Infections, Hypoglycaemia, Gastritis, Hepatitis, Chicken Pox, 
DVT, Urinary Tract Infection (UTI), Costochondritis, Anaemia, Palpitations, 
Pharyngitis, Cellulitis, Abdominal Mass, Left Ventricular Failure, Dizziness for 
investigation, Parenchymal Mass, Renal Failure, Soft Tissue injury of the thigh, 
CCF and Seizure. As noted, there is a wide range of “non-specific” diagnoses that 
 52 
 
have resulted in a documented positive D-Dimer under the umbrella of the group 
of Other.  
 
The average ages for positive D-Dimers was higher for arrhythmia, chest 
infection, chest pain, hypertension and syncope with lower age groups recorded 
for patients diagnosed with AMI, PE and other, and the youngest were those 
recorded with anxiety and headache. The mean total age was 57 years (38.0 – 
84.0), 51% of which were males. (Table 5.1 and 5.3). 
 
Average D-Dimers were recorded for Syncope, Hypertension and Arrhythmias. 
(Table 5.2 and 5.3). Lower positive D-Dimers were recorded for AMI and 
Headache. (Table 5.3). 
 
For the group diagnosed with PE, sample size was small (N=5), with 100% of D-
Dimers being positive (1.92 ± 0.70 (1.20 – 2.80)). The age group was in the lower 
age group (57.0 ± 18.4 (38.0 – 84.0)). The mean Wells Score in PE was 3.6 (3.0 - 
4.5) indicating medium probability of PE. All other diagnostic groups had low 
probability Wells Score. (Table 5.2 and 5.3). The only high score resulting from 
the calculation of the Wells Criteria was found under the group of Other 
diagnoses. (Table 5.3). Most patients had a low (<2) or moderate score (2-6) in 
terms of PE risk assessment, with few having a high score (>6), this was used as 
the pre-test probability used to assess the risk of PE. 
 
Moderate probability was found in the category of PE, Syncope, Other, GORD, 
Chest Pain, Chest Infection, Arrhythmia and Anxiety. Borderline Wells total 
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score was found in the category of AMI. (Table 5.2). There were positive D-
Dimers that had a medium probability score of significance in the Chest Pain 
category. The rest mostly had low probability scores with only  the group of Other 
having a high score. (Table 5.3). No correlation was found between D-Dimers and 
Wells Score, in fact little correlation was found between the probability score and 
diagnosis. (Table 5.2). 
 
Looking at the confirmatory tests for the positive D-Dimers, (Table 5.4), the 
category of PE has 5 patients with positive D-Dimers, all with positive CT Chest 
and CXRs. Two out of the 3 ECGs for this group were positive, and no ECHOs 
were done. Other categories were Anxiety, (1 positive ECG, 1 positive ECHO), 
Arrhythmia (1 positive ECG), Chest Infection (1 positive ECG, 1 positive CXR), 
Chest Pain (2 positive ECGs, 2 positive CXRs), Other (1 positive CT Chest, 4 
positive CXR). The other categories being AMI, CVA, GORD, Headache, 
Hypertension and Syncope had no confirmatory positive tests for the positive D-
Dimer patients within these categories. (Table 5.4). 
 
 
Table 5.1 Basic characteristics of study population (N=189) 
DIAGNOSIS N (%) AGE FEMALE GENDER (%) 
AMI 6 (3) 59 (37 - 73) 2 (33) 
ANXIETY 13 (7) 31 (19 - 45) 7 (54) 
ARRHYTHMIA 6 (3) 68 (24 - 89) 4 (67) 
CVA 5 (3) 59 (39 - 75) 1 (20) 
CHEST INFECTION 9 (5) 54 (23 - 86) 5 (56) 
CHEST PAIN 42 (22) 44 (21 - 86) 18 (43) 
GORD 19 (10) 41 (22 - 77) 12 (63) 
HEADACHE 7 (4) 42 (23 - 67) 4 (57) 
HYPERTENSION 8 (4) 58 (42 - 87) 4 (50) 
OTHER  55 (29) 46 (18 - 88) 23 (42) 
PE 5 (3) 57 (38 - 84) 3 (60) 
SYNCOPE 14 (7) 42 (22 - 87) 10 (71) 
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Table 5.2 D-Dimer and Wells results 
DIAGNOSIS N D-DIMER (Mean ± SD)(Range) WELLS SCORE TOTAL 
AMI 6 0.29 ± 0.25 (0.00 - 0.64) 2.0 ± 1.2 
ANXIETY 13 0.38 ± 0.60 (0.10 - 2.20) 2.1 ± 1.8 
ARRHYTHMIA 6 0.46 ± 0.34 (0.11 - 1.10) 2.9 ± 1.2 
CVA 5 0.27 ± 0.12 (0.12 - 0.46) 1.7 ± 1.3 
CHEST INFECTION 9 1.38 ± 1.39 (0.10 - 3.70) 2.3 ± 2.1 
CHEST PAIN 42 0.35 ± 0.66 (0.10 - 3.40) 2.9 ± 1.1 
GORD 19 0.17 ± 0.10 (0.10 - 0.48) 2.4 ± 1.6 
HEADACHE 7 0.26 ± 0.19 (0.10 - 0.54) 0.9 ± 1.5 
HYPERTENSION 8 0.36 ± 0.33 (0.10 - 0.96) 1.8 ± 2.2 
OTHER  55 0.52 ± 0.82 (0.10 - 4.00) 2.4 ± 1.9 
PE 5 1.92 ± 0.70 (1.20 - 2.80) 3.6 ± 0.8 
SYNCOPE 14 0.21 ± 0.21 (0.10 - 0.87) 2.8 ± 1.5 
 
 
 
 
 
Table 5.3 Positive for D-Dimer (N=40) 
 
      
  SCORES 
DIAGNOSIS N  
D-DIMER (Mean ± SD) 
(Range) 
WELLS TOTAL 
(Mean ± SD)(Range)  LOW MEDIUM HIGH 
AMI 2 0.59 ± 0.08 (0.53 - 0.64) 1.5 ± 2.1 (0 - 3.0) 3 3 0 
ANXIETY 3 1.24 ± 0.84 (0.68 - 2.20) 3.0 ± 2.6 (0 - 4.5) 5 8 0 
ARRHYTHMIA 2 0.81 ± 0.42 (0.51 - 1.10) 3.5 ± 0.7 (3.0 - 4.0) 2 4 0 
CHEST 
INFECTION 5 2.38 ± 1.05 (1.00 - 3.70) 2.7 ± 2.0 (0 - 4.5) 4 4 0 
CHEST PAIN 6 1.56 ± 1.22 (0.50 - 3.40) 2.9 ± 1.6 (0 - 4.5) 4 38 0 
HEADACHE 1 0.54 (0.54 - 0.54) 0 (0 - 0) 5 2 0 
HYPERTENSION 2 0.87 ± 0.13 (0.78 - 0.96) 2.3 ± 3.2 (0 - 4.5) 5 3 0 
OTHER  13 1.53 ± 1.23 (0.52 - 4.00) 2.9 ± 1.8 (0 - 6.0) 20 33 2 
PE 5 1.92 ± 0.70 (1.20 - 2.80) 3.6 ± 0.8 (3.0 - 4.5) 0 5 0 
SYNCOPE 1 0.87 (0.87 - 0.87) 4.5 (4.5 - 4.5) 3 11 0 
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Table 5.4 Performance of D-Dimer in relation to confirmatory tests and diagnoses 
 
 
 
The negative predictive value of the D-Dimer test has been found to be high in 
our study when used to predict a PE, whereas the positive predictive value was 
very low regarding the finding of a PE. The same was evident when looking at the 
D-Dimer versus the Wells Score, and when comparing the D-Dimer versus the 
CT Chest findings, whereby, in all three tables the D-Dimer was 100% but the 
positive predictive value was less than 50% (see Table 5.5, 5.6 and 5.7). 
 
The sensitivity in all the above tables of the D-Dimer versus PE, D-Dimer versus 
Wells Score and D-Dimer versus CT-Chest, in predicting a PE, was very low 
compared to the specificity which was by far higher (see Table 5.5, 5.6 and 5.7). 
Our study had a very low sample number hence the validity of these results would 
need confirmation with a much larger sample size. 
 
    
NOT 
DONE DONE 
NOT 
DONE  DONE 
NOT 
DONE DONE 
NOT 
DONE  DONE 
 
PROCEDURE 
 N 
CT 
CHEST 
CT 
CHEST ECG ECG ECHO ECHO CXR CXR 
RESULTS      Neg Pos   Neg Pos   Neg Pos   Neg Pos 
AMI 2 1 1 0 0 2 0 1 1 0 2 0 0 
ANXIETY 3 2 1 0 0 2 1 2 0 1 2 1 0 
ARRHYTHMIA 2 2 0 0 1 0 1 1 1 0 1 0 0 
CVA 0 0 0 0 0 0 0 0 0 0 0 0 0 
CHEST 
INFECTION 5 4 1 0 1 3 1 5 0 0 2 2 1 
CHEST PAIN 5 4 1 0 0 4 2 5 1 0 2 1 2 
GORD 0 0 0 0 0 0 0 0 0 0 0 0 0 
HEADACHE 1 1 0 0 0 0 0 1 0 0 1 0 0 
HYPERTENSION 2 2 0 0 0 2 0 2 0 0 2 0 0 
OTHER  12 8 3 1 4 8 0 11 1 0 6 2 4 
PE 5 0 0 5 0 3 2 4 0 0 0 0 5 
SYNCOPE 1 1 0 0 0 1 0 1 0 0 0 1 0 
 56 
 
A number of patient categories exhibited false positive results, with the highest 
number found in the category of Other, followed by the categories of Chest Pain 
and Chest Infection. Other categories of Anxiety, AMI, Arrhythmia, 
Hypertension, Headache and Syncope, also showed false positive results. 
 
There were no false negatives for D-Dimer, D-Dimer versus Wells and D-Dimer 
versus CT Scan. All five patients who had a documented PE had raised D-Dimers 
with a positive CT Chest and a moderate Wells Score. There were no negative D-
Dimers with a CT Scan finding of a PE, nor were there low Wells Scores with a 
positive finding of PE. There were also no positive CT Scans that had a negative 
D-Dimer or a low Wells Score (see Table 5.5, 5.6 and 5.7). 
 
 
Table 5.5   D-DIMER vs PE 
      
  
PE 
    
 
Positive Negative Total 
 
D-Dimer Positive 
5 37 42 
 Negative 0 147 147 
       Sensitivity 
  
2.60% 
  Specificity 
 
78% 
  Predicitve value of positive D-Dimer 11.90% 
  Predicitve value of negative D-Dimer 100% 
  
  
 
 
   
      
     Table 5.6   D-DIMER vs WELLS SCORE 
      
  
WELLS SCORE 
  
  
Positive Negative Total 
 
D-Dimer Positive 2 60 62  Negative 0 127 127 
       Sensitivity 
  
1.05% 
  Specificity 
 
67% 
  Predicitve value of positive D-Dimer 3.22% 
  Predicitve value of negative D-Dimer 100% 
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Table 5.7 D-DIMER vs CT CHEST 
      
  
CT CHEST 
  
  
Positive Negative Total 
 
D-Dimer Positive 
6 11 17 
 Negative 0 172 172 
 
      Sensitivity 
  
3.17% 
  Specificity 
 
91% 
  Predicitve value of positive D-Dimer 35.29% 
  Predicitve value of negative D-Dimer 100% 
  
 
 
 
 
6.0 DISCUSSION 
 
The D-Dimer is known to be a non-specific parameter, which can be positive for a 
wide differential of diagnoses.61,66,96 A highly sensitive D-Dimer assay will be well 
above the normal range in most patients with a PE.52,98 In our study we only looked at 
whether the D-Dimer was negative or positive, but not at the specific level of the 
positive D-Dimer. 
 
The specific D-Dimer assay performed at our hospital by AMPATH laboratories was 
the Roche Cardiac D-Dimer Cardiac Reader, which is a quantitative immunological 
assay for the detection of D-Dimer in freshly collected heparinised venous blood.74 
(Blood sample collection tubes which contain substances such as Ethylene-diamine-
tetra-acetic Acid (EDTA), citrate, sodium fluoride, should not be used).74 
 
The former test principles include the use of two monoclonal antibodies to act against 
the fibrin breakdown products which contain the D-Dimer product. The one antibody 
is gold labelled. The antibodies adhere to the D-Dimer product, forming a compound 
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which will remain and be detected in the blood plasma, after red blood cells from the 
sample are removed.74 Red cells will show visible agglutination in the presence of 
raised D-Dimer levels.41,62,74  A positive test is displayed as a red line. The more 
intense the line, the greater the accumulation of the gold labelled antibodies, the more 
positive the D-Dimer test will be. This is picked up by the cardiac reader instrument 
and is interpreted as a quantitative result.74 
 
Our research did not address time periods in which the D-Dimer was performed. This 
was looked at in two other different studies. The first being a study by Goldin and 
colleagues, who looked at the time period from the time symptoms presented, until a 
D-Dimer test was performed. The D-Dimer concentrations appeared to increase 
immediately after a thrombotic event had occurred, but then the value would start to 
decrease. It was concluded that the timing of the D-Dimer test has diagnostic bearings, 
and a health professional who suspected a DVT or PE in their patient, should bear in 
mind the time period from the onset of the patient’s symptoms, especially if a patient 
presents a few days or even a week later. The authors therefore suggested that the 
healthcare professional does not exclude a PE/DVT if the D-Dimer is negative, if 
found several days post onset of symptoms.76 They concluded that the time period had 
significant impact on the validity and relevance of the quantitative D-Dimer, which 
appears to be one week from the onset of the specific symptoms. A negative D-Dimer 
after one week from onset of the symptoms, cannot exclude a thrombotic episode in 
such a case.76  
 
Our research showed positive D-Dimers to be higher in males with a mean age group 
of 57 years (range 38 – 84 years), and was completed over three months. A 
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retrospective study by Fumeaux and Cornuz, similar to ours except over a longer 
period (six months), at a regional hospital in Switzerland, dealt with patients who were 
found to have a clinical high probability of thrombotic disease but a negative D-Dimer 
result. The authors emphasised that such a patient should undergo further 
investigations before the diagnosis of PE/DVT is excluded and looked at the negative 
predictive value of D-Dimer which, was very different to our study objective.99 It also 
showed no significant differences in age or gender in the negative D-Dimer group. 
There were 22% of patients that had a positive diagnosis of thrombotic disease. These 
latter patients were mainly young women with a moderate to high pre-test probability 
score of PE. 99 
 
Our results emphasise that a D-Dimer is non-specific, however, it is positive mostly in 
patients with PE, even in our small sample size. The remaining positive D-Dimers 
showed a significant association to chest infection that should be explored further. 
What has been documented concerning the latter, is that after 24 to 72 hours, loss of 
pulmonary surfactant as a result of a significant PE, may cause atelectasis and alveolar 
infiltrates, which are impossible to differentiate from pneumonia, where similar can be 
found by means of clinical examination and CXR.6 In such a case, the raised D-Dimer 
is thought to be a result of catabolic breakdown processes involving fibrin degradation 
within the alveoli which directly influence the D-Dimer levels.73 
 
Our study, found more males with positive D-Dimers for PE/DVT and a mean age of 
57 years (range 38 – 84 years), as compared to the average age of patients documented 
to be suffering from CAP (62 ± 12 years), with females dominating the group, in an 
article published.73 
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Our results reflected a wide range of conditions (the group of Other) for which the D-
Dimer was positive, which is supported in the literature, where pathologies such as 
malignancies, severe inflammatory disorders and sepsis (for example DIC), trauma, 
postoperative patients, stroke (acute phase), anaemia (sickle-cell), CCF, juvenile 
idiopathic arthritis, rheumatoid arthritis and ulcerative colitis are also clinical 
conditions that result in positive D-Dimer levels.73,79,91 We also found that the wide 
differential for a positive D-Dimer emphasises how non-specific D-Dimers are, thus 
having a low positive but high negative predictive value and therefore cannot be used 
in isolation to confirm a PE (see Table 5.5, 5.6 and 5.7).42,52  
 
As noted above, the D-Dimer may be raised in many other conditions including 
CVA,15 however, in our study we had negative D-Dimer results found for the CVA 
and GORD patients. There has been no documentation in literature read thus far about 
the association between GORD and the D-Dimer.76 
 
As previously noted, the average age of patients in our study was 57 years (range 38 – 
84 years), and we used the normal standard range of D-Dimer (0.1 – 0.5), in our 
single-centre study. Research shows two different retrospective, multicentre studies 
were conducted, looking at D-Dimer ranges. The first was by Douma and colleagues 
in older patients, looked at the changing D-Dimer range in this population group (50+ 
and especially in 70+years), in other words an age adjustment, which together with the 
clinical probability increases the safety margin of exclusion of PE in this sector of the 
population.55 Douma and colleagues concluded that the D-Dimer is not as useful for 
diagnosing PE, due to its reduced specificity in these older patients.55 The authors 
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hence suggested a new range for D-Dimer values in the older patient, which would be 
adjusted to age, especially when used together with the clinical pre-test probability 
score. They suggested that the latter could be a useful tool for excluding a PE in an 
older patient with a greater safety margin. The second retrospective PROLONG study 
was done in 2008, by Legnani and colleagues.  Here a group of patients was analysed 
by means of four different quantitative D-Dimer assays, in order to try and predict the 
risk of recurrence of thrombotic disease.48 The range of the D-Dimer values was 
looked at, as an additional tool to be used to identify patients with high as opposed to 
a lower probability of recurrence.48 The authors suggest, based on the data they found, 
that a slightly raised cut-off level of D-Dimer could be more useful in predicting the 
risk of recurrence of thrombotic illness. The other conclusion made by these authors 
was that an abnormal D-Dimer value, is a stronger positive predictor of PE/DVT 
recurrence compared to a normal D-Dimer value being a negative predictor.48 This 
study supports higher cut-off D-Dimer values in order to safely predict the risk of 
recurrence of PE/DVT in the elderly patient group (70+years).48 
 
More positive D-Dimers irrespective of recurrences were found in our study, in males 
with a mean age of 57 years (range 38 – 84 years), than in females. In a PROLONG 
study, which was an extended follow-up performed by Cosmi and colleagues in 2010, 
the question was raised whether sex and age together with a normal D-Dimer are risk 
factors for the recurrence of thrombotic disease.7 The conclusion (once patients that 
were on anticoagulant medications were excluded), was that recurrent thrombotic 
disease was higher in males and in patients older than 65 years. Patients with a normal 
D-Dimer who were younger than 65 years had recurrences more in males than in 
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females and both genders older than 65 years had more recurrences than females 
younger than 65 years.7  
 
In our study, regarding the Wells criteria, the patients with PE had a medium overall 
score (2 – 6), which supports and confirms the usefulness for this set of criteria in the 
risk prediction of those patients with possible PE. In other words, a medium Wells 
Score has a very high probability of a PE outcome in the final diagnosis (see Table 
5.2). Grüning and colleagues concluded similarly, that a D-Dimer assay can more 
accurately be interpreted when used in combination with a clinical pre-test probability 
score.15  
 
We found that the patients with a confirmed PE had an intermediate Wells probability 
score, and these positive PEs were found in males with a mean age of 57 years (range 
38 – 84 years). This was supported by Fedullo and Tapson, who noted that about 25% 
to 65% of patients with suspected PE had an intermediate Wells probability score, of 
which 25% to 45% of these ultimately had a confirmed PE.5 A VQ Scan confirmed 
this in 88% to 93% in this group of patients.5  
 
In our study, our patients with a confirmed PE, had an intermediate probability Wells 
Score as mentioned previously. In comparison, a study done in 2007 by Froehling and 
colleagues, to determine the sensitivity and specificity of a quantitative D-Dimer test, 
to confirm an acute PE, 15% of the CT Scans interpreted were positive for acute PE 
and D-Dimer levels were moderately raised for those with PE.100 The authors of the 
article concluded that a negative quantitative D-Dimer assay with a low pre-test 
probability score is enough for the exclusion of an acute PE.100 Our study is supported 
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by a study performed by Taira and colleagues, where three out of four patients were 
documented to have an intermediate clinical Wells probability score and were positive 
for PE on CT angiography.75 The conclusion of the latter study was that patients with 
low risk probability score and D-Dimer levels less than 500ng/ml are at low risk for 
PE/DVT, and may not need further assessment.75 
 
Our study was a retrospective study, whilst a prospective study performed by 
Gopinath and Gildes,  showed that there was definite correlation between the clinical 
findings of an experienced medical doctor which included the patient’s symptoms, 
signs, laboratory blood results and radiological investigations, and a positive result of 
a PE, which highlighted the usefulness of the Wells probability scores (“low” 
“intermediate” and “high”).51,52 This article also looked at the usefulness of a spiral 
CT Scan as an investigation that can be used as a high-negative predictive agent. No 
conclusion was reached aside from that the scoring prediction rules (such as the 
Wells) together with laboratory results and radiology should be used as a combination 
approach with the greatest reliability in terms of diagnosing PE.51,52 
 
In our study, specificity of the D-Dimer test was found to be high but sensitivity low 
(see Table 5.5), yet Brown and his colleagues, found that the specificity of the D-
Dimer assays, is generally low and hence cannot be used as the sole diagnostic test for 
exclusion of PE/DVT.79 They also emphasised that patients should have a 
confirmatory imaging test like a CT Chest if they present with a high pre-test 
probability score and/or the D-Dimer test is positive, due to the very high morbidity 
and mortality of missed diagnoses of PE/DVT.79 Agterof and colleagues looked at a 
model that would help predict possible complications in the first ten days following 
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the diagnosis of an acute PE.101 This model was thought to be useful in predicting 
which patients were likely to develop morbidity/mortality complications. This would 
assist in the planning of management of such a patient early on, in other words, which 
should be treated in hospital and which one as an outpatient.101  
 
Not all patients in our study with the final diagnosis of PE had all or even most of the 
Wells Criteria for PE (Table 5.2). Some literature notes that the Wells screening score 
is better used and more accurate in outcome in younger patients that do not have other 
co-morbid conditions or a history of previous thrombotic or thrombo-embolic 
disease.23 There is another score, called the revised Geneva Score, which has been 
compared in its accuracy to the Wells Score.94 
 
Our study as previously mentioned, was a retrospective study of 189 EU patients, and 
we only used the Wells Score for pre-test probability risk assessment. A study by 
Penaloza and colleagues in Belgium in 2011 also in an EU, compared the Wells Score 
and the Revised Geneva Score in terms of their accuracy in assessing their pre-test 
probability in predicting PE.102 Two prospective studies were used which had data 
from 339 patients, suspected to have PE.102 A prospective assessment using the Wells 
Score, was used for the pre-test probability of a PE in these patients, with the Geneva 
Score calculated retrospectively. They concluded that the Wells Score appeared to be 
more accurate in patients suspected to be suffering from a PE.102 
 
Our study used the Wells Score only, as part of our pre-test risk stratification. We 
found that the Wells Score had a low sensitivity and but high specificity in diagnosing 
PE (see Table 5.6). A study by Wong and colleagues, performed in Australia in 2011, 
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compared the accuracy of the Wells Score and Revised Geneva Score, in diagnosing 
PE.103 The authors felt that the Wells Score is commonly a subjective score, while the 
Revised Geneva Score, a more recent score was more objective.103 This study used a 
smaller population group (98), compared to ours (189), and was also performed in an 
EU.  Similarly to our study, they found the Wells Score to have a lower sensitivity, 
however, a higher specificity than the Revised Geneva Score, although the accuracy of 
both appeared to be almost the same.103 The authors concluded that a larger 
prospective study is needed to confirm that a Wells Score with higher specificity could 
safely select the patients requiring CT Scans of the chest.103  
 
We assessed a fairly small population group (189), using the Wells probability score. 
Patients with confirmed PE were found to have a moderate Wells Score. Those with a 
low Wells Score did not have a positive diagnosis of PE. A study by Bertoletti and his 
colleagues in 2011, looked at the prognostic value of the Revised Geneva Score in a 
population group where PE has been excluded.104 This was a retrospective study of 
data gathered prospectively between six teaching medical centres involving 
Switzerland, Belgium and France.104 This study involved a larger population group 
(1334) compared to ours. The authors concluded that the initial probability assessment 
score, using the Revised Geneva Score, can correlate with the patient’s probable 
outcome. Especially patients with a low probability score appeared to have a better 
prognosis.104  
 
Our study was a retrospective study of only 189 patients, and we used the Wells Score 
to predict clinical probability of PE in our population group. A study by Hogg and 
colleagues performed in the UK in 2011, compared the BTS Score to the Wells Score 
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in its accuracy in diagnosing PE.105 This was a prospective study of 779 patients. The 
Wells Score appeared to be the more accurate score for diagnosing PE.105  
 
Our study, did not look at any specific vitals, unlike a study performed by 
Singanayagam and colleagues, which had a different objective to ours, as it looked at 
whether adding biomarkers, specifically a Troponin I, to the PE Severity Index 
(PESI), which is a thirty day mortality predictive scoring system, would improve the 
accuracy of the PESI.106 This was a retrospective study, similar to ours, however it 
specifically looked at normotensive patients who were diagnosed with acute PE.106 
The outcome showed that this combination definitely improved the predictive value of 
the mortality scoring system, which could then be helpful when planning the initial 
management of a patient with acute PE who has a normal BP.106  
 
Our study, compared to Hariharan and colleagues study, was also a retrospective 
study, however the authors looked at the PESI. They performed a retrospective study 
of EU patients with PE presenting between May 2006 and April 2008, in order to see 
if the PESI could predict which patients would be free of clinical complications during 
hospitalisation, these complications included different forms of morbidity or 
mortality.107 The study included 245 patients diagnosed with PE, of which 47% were 
male with an average age of 57 ± 17 years,107 compared to our population group of 
189 (only 5 diagnosed with PE), with an average age of 57 years (range 38 -84 years), 
and in our PE category of patients, the dominant gender being female (60%). 
Hariharan and colleagues concluded that the PESI was not a comprehensively safe 
predictive index scoring system in terms of prognostic outcome, hence improvements 
are necessary in this scoring system.107  
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In a study very different to ours, with a very different objective, which was a 
prospective multicentre study, a very large sample size of patients (7940) was used.108 
Courtney and colleagues, used the clinical examination and history in order to predict 
whether a PE is present in EU symptomatic patients.108 Thirteen variables were 
assessed in terms of their predictive value regarding the presence of a PE. The authors 
validated that variables such as family history of thrombotic disease, thrombosis in the 
absence of malignancy, pleuritic chest pain, recent surgery, use of hormone 
replacement therapy (especially oestrogen), which are part of accepted pre-test risk 
stratification scoring systems, increase the likelihood of  the presence of a thrombotic 
disorder such as PE or DVT.108 This study was unique as it has been the only study to 
date that compared and quantified the predictive value of the aforementioned variables 
as regarding the presence or absence of a PE in symptomatic EU patients.108  
 
As regarding the confirmatory tests used in our study, we observed that in the 
confirmed PE category of patients, all five CT Chest and CXRs were positive, which 
confirmed these studies to be important in the final diagnosis of PE. (Table 5.4). This 
has been supported by studies that documented that Spiral CTs can pick up a PE with 
a sensitivity of more than 90% (53% and 100%), which may be as small as 2mm, with 
a specificity of around 95% (80% to 100%).41,42,51  Other literature has noted that CT 
scanning can pick up alternate diagnosis in up to 57% of patients.4,10,47 The one 
limitation of significance associated with Spiral CT scanning, is the possibility of 
missing small sub-segmental PEs (false-negative) or falsely detected PEs (false-
positive).18,52 The Single Detector Helical scanner may miss a sub-segmental PE 
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hence its sensitivity is found to be variable across a variety of studies.41 The proximal 
thrombi are usually detected easily by a CT Scan.18,52 
 
In our study, we used the Wells Score clinical probability, together with the D-Dimer 
and confirmatory tests to diagnose or exclude PE. Of the five patients who were 
diagnosed with a PE, a CT Spiral Scan of the chest was one of the confirmatory tests. 
Only the Spiral CT was used in our study unless a DVT was strongly suspected, in 
which case, a Doppler Ultrasound Scan of the limb involved was also ordered. All 
patients had ECGs and CXRs preceding the scan as part of their set of confirmatory 
tests. 
 
We found that the negative predictive value of a negative D-Dimer and a low pre-test 
probability Wells Score, has a high negative predictive value for PE (see Table 5.6 
above). Similarly in a review published by Segal and colleagues, it was strongly 
recommended to use the clinical prediction scoring systems to assess pre-test 
probability of the recurrence of DVT/PE, before using extra confirmatory tests.41 It 
was also suggested that if the D-Dimer assay is normal and a low clinical pre-test 
probability score is found, this resulting negative predictive value may preclude the 
need to use other confirmatory tests especially the more expensive radiological tests 
such as the spiral CT.41 
 
The CT Chest can now be available as either a Single Detector Helical Scan or Multi 
Detector Scan, however, the latter scans are very new in terms of their sensitivity and 
specificity in detecting unusually located PEs.41 In our study, our positive PE findings 
were documented and confirmed by means of clinical judgement and findings as well 
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as the Wells probability score, D-Dimer testing and finally confirmatory tests, mainly 
the spiral Chest CT Scan. 
 
Regarding the ECG, most common and non-specific ECG findings occurring in the 
presence of a PE, are an increased HR and non-specific ST-T abnormalities,3,6 which 
was supported in our study. We found tachycardia in most of our positive PE patients. 
We also agreed that the CXR is far from diagnostic and showed very little. It helped 
however, to exclude other clear diagnoses such as pneumonia and 
haemo/pneumothorax.3 
 
Our study was mostly different to Sakamoto and colleagues study, excepting that both 
were retrospective studies performed in an EU, as well as all our patients with positive 
D-Dimers also had a spiral CT Chest for confirmation of diagnosis. They looked at the 
usefulness of the D-Dimer test in differentiating Acute Aortic Dissection (AAD) and 
acute PE from AMI.109 These are all conditions that present with acute chest pain, 
affect the coagulation pathway and often present with similar signs and symptoms. 
This study showed that AAD and PE patients had D-Dimer values that were 
considerably raised compared to those of patients suffering from an AMI. The D-
Dimer cut off value of 5.0g/ml was used in distinguishing the latter conditions with a 
specificity of 90% and sensitivity of 68%.109 The authors concluded that the D-Dimer 
assay can be used as a screening tool to differentiate AAD and PE from AMI. A CT 
Chest would be the radiological investigation of choice, with any D-Dimer level 
>5.0g/ml prioritised over the coronary angiography in the latter case.109  
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Our study showed a high specificity as well as a high negative predictive value of the 
D-Dimer, in diagnosing PE (see Table 5.5). Guttte and colleagues and Türedi and 
colleagues, look at a marker (BNP) and its prognostic value in predicting which PE’s 
will complicate post admission to hospital, in two separate studies.6,57,110 These 
complications may include among others, right ventricular dysfunction in an acute 
phase of a PE.57,110 There is also mention of the Ischemia-Modified Albumin 
(IMA),110 which is suggested in literature to be 93% sensitive and 75% specific for 
PE. This is thought to be even more accurate in terms of prognosis when combined 
with the Wells and Geneva screening scores.6 However, other sources of literature 
believe the D-Dimer is a much more reliable marker for the prognosis of a PE as 
compared to the new marker – the IMA.110 
 
Our study did not find the ECHO to be a useful diagnostic tool but, due to our low 
sample number, this would have to be verified. In the literature, ECHO results have 
been found to help guide treatment as well as detect large PEs.3 Clots moving through 
the heart to the lungs can be confirmed via ECHO. There is also intravascular 
ultrasound that can be used by the bedside to see large clots.3 The ECHO clinical 
findings may include a hypokinetic or enlarged right ventricle wall. The ECHO can 
also pick up pulmonary hypotension signs.6 A second article does not believe that the 
cardiology ECHO can be used as a diagnostic tool for PE, instead it noted the trans-
oesophageal ECHO to have a sensitivity of 60% to 80% and a specificity of 95% to 
100% in detection of a PE.52 In our study, an insignificant number of ECHOs were 
done as part of the diagnosis of the positive PEs, however, a recommendation has 
been made to use an ECHO in combination with the spiral CT or VQ Scan, which in 
combination may help in diagnosing massive PEs.11 
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We looked at all patients that came through the EU within a three month period who 
had a D-Dimer test done, however, an EU based retrospective study performed by 
Taira and colleagues, specifically assessed those with venous thrombo-embolism.75 
The study used a computerised data base in order to determine the rate of thrombotic 
disease in the patients with suspected PE/DVT, and looked at the D-Dimer level as a 
tool for risk stratification.75 The patient mean age was 48 ± 19 years with 63% being 
females.75,93 Low risk patients with a moderate D-Dimer value (200 to 500ng/ml) were 
investigated.75,93  
 
We conducted a similar study to Kline and colleagues, however, they included a very 
large number of patients 2303, compared to our smaller sample of 189 patients.66 The 
former study used patients of all ages unlike ours that only involved adults (>18 
years). Both studies enrolled patients with specific symptoms including SOB, chest 
pain, syncope and vitals such as tachycardia.66 
 
Our study found 21.16% of patients had a positive D-Dimer for a number of 
conditions, of which the highest positive D-Dimers were recorded for PE and 
concluded that the D-Dimer was done in only a fifth of patients seen in our private EU 
and positive in less than 50% of cases, the D-Dimer test yield was highest in patients 
with PE as their final diagnosis. The D-Dimer test we used (Roche Cardiac 
Quantitative Immunological Assay), had high negative predictive value in more than 
half of the non-PE diagnoses. We used the Wells Score for pre-test probability values 
and found that the patients who had a positive diagnosis of PE had mostly a moderate 
Wells Score.66,74 In comparison, the previously noted study performed by Kline and 
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colleagues which involved EU patients, looked at a different D-Dimer assay to ours – 
the “Point of Care” D-Dimer testing, as a rapid tool for exclusion of PE in the EU 
situation.66 The sensitivity of this assay was found to be 80.6% and the specificity 
72.5%.66 They found a 4.7% of patients positive for the diagnosis of PE. They also 
found that patients with low risk predictive score prior to the D-Dimer testing and 
subsequently negative D-Dimer results had an almost 0% outcome of diagnosis of 
PE.66 They concluded that the simple D-Dimer assay (the point-of-care assay) had 
moderate sensitivity as well as relatively high specificity in the diagnosis of PE in a 
low risk group of emergency department patients. They used the Canadian Score and 
the Charlotte Criteria.66 
 
There are similarities and differences when comparing our study to that performed by 
Stein and colleagues in 2011. Theirs differed to ours as it was a study on hospitalised 
patients with different objectives. The authors looked at the prognostic value of the D-
Dimer assay when taken from a stable patient diagnosed with a PE.111 This showed 
mixed results where there was no direct correlation between very high D-Dimer levels 
and mortality from PE in in-hospital stable patients. The similarities were that the 
population group was also small (292), and it was a retrospective study using 
documentation from patient charts.111 
 
Our study used the Wells Criteria together with the D-Dimer value in order to risk 
stratify patients suspected to have PE. No computerised algorithm was used as part of 
our decision making and final results, as far as confirmation of the diagnosis of PE in 
this group of patients. Those patients that were found to have a positive diagnosis of 
PE, had mostly a moderate Wells Score, positive D-Dimer, as well as positive findings 
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on CT Chest. In comparison, Drescher and colleagues, tried to include modified Wells 
Criteria into a computerised programme in order to assist the emergency physician 
with their evaluation of a suspected PE.112 This kind of algorithm was looked at to 
assist in reducing the number of requested CT Chest investigations ordered by 
emergency physicians in EUs. Unlike our study, it was a prospective interventional 
study that used a retrospective pre-interventional group of patients for comparative 
purposes.112 The authors found that this computerised algorithm definitely was 
associated with an improved selection of patients for CT Chest with overall more 
positive results. However, it was time consuming, hence not used consistently by the 
emergency physicians.112  
 
A study in 2011, performed by Lee and colleagues, looked at the cost of diagnostic 
investigations in patients with high, moderate or low clinical pre-test probability of  
PE.113 The authors suggested that a diagnostic strategy of performing a D-Dimer test 
followed by a CT Chest was most cost effective.113 This, as opposed to the traditional 
VQ Scan that was usually followed by pulmonary angiography and CT.113 This was 
very different to our study objective, although we did use the same diagnostic strategy 
of a CT Chest rather than a VQ Scan, following a positive D-Dimer result in a patient. 
 
We looked at the usefulness of the D-Dimer assay in the diagnosis of PE, using patient 
data that was collected over three months, irrespective of the day of the week. A study 
by Gallerani and his colleagues, looked at the difference in mortality between patients 
hospitalised for an acute PE during the weekend as opposed to during the week.114 The 
aim was to focus on the possible part-time availability of medical expertise, specific 
management, as well as specific radiological investigations in some hospitals in 
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Italy.114 The conclusion of this study was that weekend admissions for PE do have an 
association with worse prognostic outcome and higher mortality compared to those 
admitted during the week.114 As noted, the two studies have completely different 
objectives. 
 
The group of Other which comprised a wide range of different diagnoses, as recorded 
in the Results section of this report was another major limitation of our study. Each 
one of these different diagnoses was limited to very few patients and therefore, was 
grouped under Other. Due to this fact, the high percentage of positive D-Dimers 
(24%), recorded for this category, was not a true representation, as the individual 
groups of diagnoses were extremely small within this big group.  
 
A large diversity of patients presents to our private EU which is an EU with differing 
clinical severity levels of disease, and different financial predicaments, some patients 
being on a medical aid or insurance and others private paying patients. They may also 
be clinically stable or may require medical intervention to be stabilised, may present 
with minor SOB which has lasted for days or severely incapacitated by acute 
symptomatology. The medical doctors treating these patients are updated in all three 
emergency courses (Advanced Trauma Life Support (ATLS), Advanced Cardiac Life 
Support (ACLS), Paediatric Advanced Life Support (PALS)), and many are 
specialising and are also working at the provincial hospitals. 
 
The patients who have no financial resources, will not be able to afford the D-Dimer 
and Spiral CT of the chest. These will then have to be referred to the provincial 
hospitals where there will be time delays in obtaining the latter tests which may 
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amount to several days, rather than the one to two hours spent waiting for these tests 
to be done in our private EU. This can compromise the patient’s health further and 
may have a fatal outcome as many may look well despite an underlying major PE.  
 
We used a small patient population (189), our average age was 57 years (38.0 – 84.0), 
49% of which were female patients. Our patient population was from a single EU and 
we used the Wells predictive variables in conjunction with a D-Dimer and further 
confirmatory tests, that were done on some of the patients. Courtney and colleagues 
looked at the predictive value of thirteen “new” parameters, as compared to the 
previously used prediction criteria. They used a prospective multi-centre study from 
many emergency departments. A D-Dimer CT angiography, or VQ Scan was 
performed. Thirteen new parameters added to twelve pre-existing variables. A very 
large sample size (7940) was used, with an average age of 49± 17 years, 67% of 
which were female. There were several parameters of the “new” listed ones that 
showed a strong positive predictive value of PE/DVT and they included pleuritic chest 
pain and family history of thrombotic disease, as well as an individual’s history of 
thrombophilia. This study also reaffirmed previous known positive predictive 
variables such as one month post-operative period, previous history of thrombosis, 
history of cancer among other.115 
 
In our retrospective study performed in a private EU at a secondary facility, we used a 
different D-Dimer test, the Quantitative Roche Assay. Our sample size was small 
(189) and it was performed over three months. Our sample included all patients who 
had a D-Dimer test done, some had confirmatory tests done depending on the doctor’s 
working diagnosis at the time of patient assessment. A study by Lucassen and 
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colleagues was performed in a primary care facility in the Netherlands, where the 
Wells Criteria were used in combination with the D-Dimer test (Point-of-Care), 
whereby a PE was excluded with a moderate degree of certainty. This prospective 
study included a very large sample size of 3306 patients over almost a two year 
period. The patients who had a normal D-Dimer were not considered to have a PE but, 
all others had a spiral CT and a three months follow up for recurrence of thrombosis 
was done. It was concluded that the use of this D-Dimer test, with the Wells predictive 
criteria, excluded a PE safely with only a reasonable degree of effectiveness.116 
 
 
7.0 CONCLUSION  
 
Our results have shown that a PE is easily confused with multiple other conditions. 
We have also observed from our results, that the Wells Criteria seem to be a sound 
screening test for the diagnosis of a PE, and that the D-Dimer test is useful for its 
positive and negative predictive values, and is extremely reliable as a negative 
predictive marker. 
 
Our study confirmed that the clinical presentations of patients with PE is non-specific, 
however the best known screening test for PE – the D-Dimer, which may be positive 
in a wide variety of diagnoses, is useful in establishing the diagnosis of PE, when it is 
found to be positive.  
 
The documented Wells Score Criteria together with a CT Chest, may help further in 
excluding the wide differential available for a positive D-Dimer. Although we only 
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used the Wells Score, there are other scores such as the Revised Geneva Score that 
have proved to be effective in other studies.42 Our study also found the negative 
predictive value of the D-Dimer to be high, but the positive predictive value to be low. 
The specificity of the D-Dimer was high yet we found the sensitivity to be low as 
regards the diagnosis of PE in our group of patients. Therefore this study confirmed 
that the predictive value of a D-Dimer together with the Wells Criteria is improved 
with the use of a Spiral CT of the Chest. 
 
This study presented with many challenges including a small sample size, missing 
data, the need to rely on a laboratory technician to perform the D-Dimer assay and 
periods of equipment malfunctions. There were often periods of equipment failure 
whereby the D-Dimer test and/or CT Chest would take longer to obtain during the 
allocated study period in which the data was collected, and a large group of Other that 
included a diversity of diagnoses. The D-Dimer was done in only a fifth of patients 
seen at the MMC private hospital EU and was positive in less than half of these cases. 
This test appears to be grossly underutilised in the private EU even though it has the 
highest yield in the diagnosis of PE and a high negative predictive value in non-PE 
diagnoses.  
 
Our study has highlighted the need in the future, to do more studies with larger sample 
groups, as there was an inadequate sample group to base firm conclusions upon. 
 
This study has never been undertaken in South Africa before in a private emergency 
setting, although it proved to be inadequate, due to the very small sample size of 
patients with PE. There is a need to do a larger study, possibly over a longer time 
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period, to ascertain the true usefulness of the D-Dimer test in our EU population, in 
order to confirm whether this is an adequate tool for PE screening. 
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APPENDIX A: D-Dimer study data collection sheet 
 
 
 
1.DEMOGRAPHIC INFORMATION 
 
DATE                     :______________________________ 
 
STUDY NO            :______________________________ 
 
BIRTH DATE        :_______________________________ AGE:_____ 
 
 
2. PRESENTING SYMPTOMS 
CHEST PAIN:                                                                 Present          Absent           Not evaluated 
SHORTNESS OF BREATH:                                          Present          Absent           Not evaluated 
PALPITATIONS:                                                            Present          Absent           Not evaluated 
NAUSEA/VOMITING:                                                   Present          Absent           Not evaluated 
OTHER SYMPTOMS:______________________        Present          Absent           Not evaluated 
 
 
3. WELLS CRITERIA FOR PULMONARY EMBOLISM 
 
VARIABLE                SCORE 
 
CLINICAL SIGNS OF DVT 
 
  No                Yes      +3 points 
 
ALTERNATIVE DIAGNOSIS LESS PROBABLE THAN PE   No                Yes      +3 points 
 
HEART RATE > 100 BPM    No                Yes      +1.5 points 
 
IMMOBILIZATION OR SURGERY < 4 WEEKS AGO    No                Yes      +1.5 points 
 
PREVIOUS DVT OR PE    No                Yes      +1.5 points 
 
HAEMOPTYSIS    No                Yes      +1 point 
 
CANCER    No                Yes      +1 point 
 
   TOTAL SCORE _________   
 
PRE-TEST PROBABILITY              Low (score <2)                Moderate (score 2 – 6)                  High (score >6) 
 
4. D-DIMER TEST RESULTS 
 
 
 
5. CONFIRMATORY DIAGNOSTIC TESTS 
 
CT SCAN                                         Negative                    Positive _______________________ 
 
V/Q SCAN                                        Negative                    Positive _______________________ 
 
ECG                                                   Negative                    Positive _______________________ 
 
ECHO                                                Negative                    Positive _______________________ 
 
PULMONARY ANGIO                    Negative                    Positive _______________________ 
 
OTHERS ________________           Negative                    Positive _______________________ 
 
 
 80 
 
APPENDIX B:  Wits Human Research Ethics Clearance Certificate 
 
 81 
 
APPENDIX C:  Letter of approval of change of title 
 
 82 
 
 
 
APPENDIX D:  Letters of permission 
 
 
 -­‐-­‐-­‐-­‐-­‐Original	  Message-­‐-­‐-­‐-­‐-­‐	  
From:	  Zika,	  Daniel	  [mailto:DZika@webmd.net]	  	  
Sent:	  08	  September	  2010	  22:11	  
To:	  Mandy	  Behr	  
Subject:	  RE:	  PERMISSION	  TO	  USE	  COPY-­‐WRITTEN	  MATERIAL	  
	  
Dear	  Dr	  Schur,	  	  
	  
Thank	  you	  for	  your	  query	  and	  interest	  in	  eMedicine.	  In	  response	  to	  your	  
email	  below,	  eMedicine	  grants	  you	  permission	  to	  reprint	  image	  #1	  from	  the	  
eMedicine	  article	  Pulmonary	  Embolism.	  	  There	  is	  no	  fee	  associated	  with	  this	  
permission.	  	  
	  
Such	  reproduction	  will	  be	  for	  the	  following	  purpose	  only:	  	  Masters	  
material.	  This	  permission	  is	  limited	  to	  educational	  and/or	  nonprofit,	  
noncommercial	  use	  and	  does	  not	  include	  republishing	  or	  redistribution	  for	  
any	  commercial	  or	  for-­‐profit	  purpose.	  	  
	  
eMedicine	  retains	  copyright	  for	  the	  material	  that	  you	  reproduce	  as	  part	  of	  
this	  agreement.	  Please	  include	  the	  following	  credit	  line	  and	  copyright	  
acknowledgement	  with	  your	  reproduction:	  	  
	  
Image	  reprinted	  with	  permission	  from	  eMedicine.com,	  2010.	  Available	  at:	  	  
http://emedicine.medscape.com/article/759765-­‐overview.	  	  
	  
Please	  feel	  free	  to	  contact	  me	  at	  any	  time	  if	  you	  have	  further	  questions	  or	  
requests.	  	  
	  
	  	  
Dan	  Zika	  
	  
Associate	  Editor/Permission	  Coordinator	  
	  
dzika@webmd.net	  
	  
Phone	  &	  Fax:646-­‐674-­‐6905	  
	  
	  	  
	  
From:	  Mandy	  Behr	  [mailto:mandy@behr.co.za]	  	  
Sent:	  Sunday,	  September	  05,	  2010	  10:47	  AM	  
To:	  Editor2	  
Cc:	  Johnny	  Mahlangu	  
Subject:	  PERMISSION	  TO	  USE	  COPY-­‐WRITTEN	  MATERIAL	  
	  
Dear	  Sir/Madam	  
	  
 83 
 
I	  am	  currently	  doing	  my	  Masters	  in	  Emergency	  Medicine	  at	  the	  University	  of	  
Witwatersrand,	  South	  Africa.	  I	  would	  like	  to	  ask	  you	  for	  permission	  to	  use	  
some	  of	  your	  copy-­‐written	  material	  in	  my	  assignment.	  	  
The	  material	  I	  am	  referring	  to	  is	  the	  illustration:	  “The	  pathophysiology	  of	  
pulmonary	  embolism”.	  Sutherland	  SF.	  Pulmonary	  Embolism.	  emedicine	  updated	  
May	  8,	  2009,	  page	  2	  of	  21.	  
	  
Awaiting	  your	  response.	  
	  
Sincerely	  
Dr	  Mandy	  Schur	  
	  
	  
-­‐-­‐-­‐-­‐-­‐Original	  Message-­‐-­‐-­‐-­‐-­‐	  
From:	  Zika,	  Daniel	  [mailto:DZika@webmd.net]	  	  
Sent:	  08	  September	  2010	  23:09	  
To:	  Mandy	  Behr	  
Subject:	  RE:	  PERMISSION	  TO	  USE	  COPY-­‐WRITTEN	  MATERIAL	  
	  
Dr	  Schur,	  
	  
As	  you	  have	  noted,	  the	  images	  are	  courtesy	  of	  Justin	  Wong,	  MD.	  I	  cannot	  
grant	  permission	  for	  those	  images	  that	  we	  do	  not	  have	  copyright	  of	  and	  I	  
have	  no	  contact	  information	  for	  Dr	  Wong.	  	  eMedicine	  can	  grant	  permission	  to	  
use	  the	  2	  tables	  listed	  below.	  	  The	  same	  terms	  of	  the	  other	  images	  apply.	  	  
If	  you	  have	  any	  questions,	  please	  let	  me	  know.	  
	  
	  	  
Dan	  Zika	  
Associate	  Editor/Permission	  Coordinator	  
dzika@webmd.net	  
Phone	  &	  Fax:646-­‐674-­‐6905	  
	  	  
From:	  Mandy	  Behr	  [mailto:mandy@behr.co.za]	  	  
Sent:	  Sunday,	  September	  05,	  2010	  11:04	  AM	  
To:	  Editor2	  
Cc:	  Johnny	  Mahlangu	  
Subject:	  PERMISSION	  TO	  USE	  COPY-­‐WRITTEN	  MATERIAL	  
	  	  
Dear	  Sir/Madam	  
	  
With	  regards	  to	  my	  last	  email,	  I	  would	  also	  like	  to	  request	  permission	  to	  
use	  the	  following	  illustrations	  from	  emedicine,	  Pulmonary	  Embolism,”	  A	  
chest	  radiograph	  with	  normal	  findings	  in	  a	  64-­‐year-­‐old	  woman	  who	  presented	  
with	  worsening	  breathlessness”.	  Kamangar	  N,	  McDonneli	  MS,	  Sharma	  S.	  
Pulmonary	  Embolism.	  (Page	  11	  of	  47)	  	  and	  “A	  posteroanterior	  chest	  
radiograph	  showing	  a	  peripheral	  wedge-­‐shaped	  infiltrate	  caused	  by	  pulmonary	  
infarction	  secondary	  to	  pulmonary	  embolism.	  Hampton	  hump	  is	  a	  rare	  and	  
nonspecific	  finding”.	  Courtesy	  of	  Justin	  Wong,	  MD.	  Kamangar	  N,	  McDonneli	  
MS,	  Sharma	  S.	  Pulmonary	  Embolism.”	  (Page	  11	  of	  47)	  	  Also	  Tables	  1	  and	  2	  on	  
pages	  8/9	  of	  47.	  
	  
Thanks	  again.	  
	  
Sincerely	  
Dr	  Mandy	  Schur	  
 84 
 
	  
 
 85 
 
	  	  
	  
	  
	  
	  
 86 
 
REFERENCES 
(1) Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog  Cardiovasc  Disc 
1975;17:259-270. 
(2) Ryu JH, Olson EJ, Pellikka PA. Clinical recognition of pulmonary embolism: Problem 
of unrecognized and asymptomatic cases. Mayo  Clin  Proc 1998;73:873-879. 
(3) Patocka C, Nemeth J. Pulmonary embolism in paediatrics. The Journal of Emergency 
Medicine 2011. 
(4) Tapson VF. Acute pulmonary embolism. Review article. The New England Journal of 
Medicine 2008;358:1037-1052. 
(5) Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. The New 
England Journal of Medicine 2003;349:1247-1256. 
(6) Sutherland SF. Pulmonary embolism. 2009; Available at: 
http://emedicine.medscape.com/article/759765. Accessed 05/04, 2010. 
(7) Cosmi B, Leganani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Sex, age and 
normal post-anticoagulation D-Dimer as risk factors for recurrence after idiopathic venous 
thrombo-embolism in the prolong study extension. J  Thromb  Haemost 2010;8(9):1933-
1942. 
(8) Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United 
States, 1979-1998: An analysis using multiple-cause mortality data. Arch  Intern  Med 
2003;163(14):1711-1717. 
(9) Riedel M. Diagnosing pulmonary embolism. Postgrad  Med  J 2004;80(944):309-319. 
 87 
 
(10) Sinert R, Foley M. Clinical assessment of the patient with a suspected pulmonary 
embolism. Ann  Emerg  Med 2008;52:76-79. 
(11) Langan CJ, Weingart S. New diagnostic and treatment modalities for pulmonary 
embolism: One path through the confusion. The Mount Sinai Journal of Medicine 
2005;73(2):528-541. 
(12) Memorial Sloan-Kettering Cancer Centre. Accuracy of the D-Dimer assay for the 
exclusion of pulmonary embolism in a high risk oncologic population. ClinicalTrials.gov. 
2008; Available at: http://clinicaltrials.gov/et2.show.NCT00615147. Accessed 29/03, 
2011. 
(13) Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Brant R, et al. D-Dimer for the 
exclusion of acute venous thrombosis and pulmonary embolism. Annals of Internal 
Medicine 2004;140(8):589-602. 
(14) Adam SS, Key NS, Greenberg CS. D-Dimer antigen: Current concepts and future 
prospects. Blood 2009;113(13):2878-2887. 
(15) Grüning T, Khonsari M, Vivian GC, Nokes T. Can plasma D-Dimer predict the result 
of a ventilation – perfusion scan? Clin  Imaging 2010;34:179-184. 
(16) Wikipedia. Virchow's triad. 2012; Available at: 
http:://en.wikipedia.org/wiki/Virchow's_triad. Accessed 9/9, 2012. 
(17) Shipley C. Pulmonary Embolism - a review. Available at: 
http://www.trialimagestore.com/article_pulmonary_embolism.html. Accessed 9/9, 2012. 
 88 
 
(18) Kamangar N, McDonneli MS, Sharma S. Pulmonary embolism. Available at: 
http://emedicine.medscape.com/article.com/article/300901. Accessed 05/04, 2010. 
(19) Kabrhel C, Courtney DM, Camargo CA, Plewa MC, Nordenholz K, Moore CL, et al. 
Factors associated with positive D-Dimer results in patients evaluated for pulmonary 
embolism. Acad  Emerg  Med 2010;17(6):589-597. 
(20) Cosmi B, Palareti G. Update on the predictive value of D-Dimer in patients with 
idiopathic venous thrombo-embolism. Thromb  Res 2010;125(2):S62-S65. 
(21) Elton DR. Pulmonary Embolism. Available at: 
http://www.lexingtonpulmonary.com/edu/pe/pe.html. Accessed 12/11, 2012. 
(22) Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous 
thrombo-embolism after major trauma. N  Engl  J  Med 1994;331(24):1601-1606. 
(23) Stein PD, Beemath A, Matta F, Weg JG, Yusen RD, Hales CA, et al. Clinical 
characteristics of patients with acute pulmonary embolism: data from PIOPEDII. 
Am  J  Med 2007;120(10):871-879. 
(24) Wahl WL, Brandt MM. Potential risk factors for deep venous thrombosis in burn 
patients. Journal of Burn Care & Rehabilitation 2001;22(2):128-131. 
(25) Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ. Factors 
associated with correct antemortem diagnosis of major pulmonary embolism. AM  J  Med 
1982;73:822-826. 
 89 
 
(26) Tanizawa K, Nakatsuka D, Tanaka E, Inoue T, Sakuramoo M, Minakuchi M, et al. 
Pulmonary thrombosis with transient Antiphospholipid Syndrome after Mononucleosis-
like illness. Internal Medicine Case Report 2009;48:1231-1234. 
(27) Matsumoto T, Wada H, Nishiyama H, Hirano T, Sakakura M, Nishii K, et al. 
Hemostatic abnormalities and changes following bone marrow transplantation. 
Clin  Appl  Thromb  Hemost 2004;10:341-350. 
(28) Streetly M, Hunt BJ, Parmar K, Jones R, Zeldis J, Schey S. Markers of endothelial 
and haemostatic function in the treatment of relapsed myeloma with the 
immunomodulatory agent Actimid<SUP>TM</SUP>(CC04047) and their relationship 
with venous thrombosis. 2005;74:293-296. 
(29) Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb  Res 
2006;118:555-568. 
(30) Territo MC, Rosove MH. Cyanotic congenital heart disease: Haematologic 
management. J  Am  Coll  Cardiol 1991;18(2):320-322. 
(31) Petersdorf RG, Adams RD, Braunwald E, Isselbacher KJ, Martin JB, Wilson JD 
editors. Harrison's Principles of Internal Medicine. Tenth ed. Japan: McGraw-Hill Book 
Company Japan Ltd.; 1983. 
(32) Berkow R editor. The Merck Manual. Sixteenth ed. U.S.A.: Merk Research 
Laboratories; 1992. 
(33) Wyatt JP, Illingworth RN, Clancy MJ, Munro P, Robertson CE. Oxford Handbook of 
Accident & Emergency Medicine. U.S.A.: Oxford University Press; 2004. 
 90 
 
(34) Mohan JS, Lip GY, Wright J, Bareford D, Blann AD. Plasma levels of tissue factor 
and soluble E-selectin in sickle cell disease: Relationship to genotype and to inflammation. 
Blood Coagulation Fibrinolysis 2005;16:209-214. 
(35) Eldor A, Rachmilewitz A. The hypercoagulable state in thalassemia. The American 
Society of Hematology 2002;99(1):36-43. 
(36) Molecular Genetic Testing in Mainstream Medicine. Venous thrombosis and the 
Factor V (Leiden) mutation. Available at: http://www.mostgene.org/gd/gdvol14b.htm. 
Accessed 16/01, 2011. 
(37) Michiels JJ, Schroyens W, De Backer W, Van Der Planken M, Hoogsteden H, 
Pattynama PM. Non-invasive exclusion and diagnosis of pulmonary embolism by 
sequential use of the rapid ELISA D-Dimer assay, clinical score and spiral CT. Int  Angiol 
2003;22(1):1-14. 
(38) Nchimi A, Ghaye B, Noukoua CT, Dondelinger RF. Incidence and distribution of 
lower extremity deep venous thrombosis at indirect computed tomography venography in 
patients suspected of pulmonary embolism. Thromb  Haemost 2007;94(4):566-572. 
(39) Ferguson JL HD. Portal vein thrombosis: An unexpected finding in a 28-year-old 
male with abdominal pain. J Am Board Fam Med 2008;21(3):237-243. 
(40) Laack TA, Goyal DG. Pulmonary embolism: an unsuspected killer. 
Emerg  Med  Clin  N  Am 2004;22:961-983. 
(41) Segal JB, Eng J, Tamariz LJ, Bass EB. Review of the evidence on diagnosis of deep 
venous thrombosis and pulmonary embolism. Annals of Family Medicine 2007;5:63-73. 
 91 
 
(42) Sanchez O, Planquette B, Meyer G. Update on acute pulmonary embolism. 
Eur  Respir  Rev 2009;18:137-147. 
(43) Hugli O, Righini M, Le Gal G, Roy PM, Sanchez O, Verschuren F, et al. The 
pulmonary embolism rule-out criteria (PERC) rule does not safely exclude pulmonary 
embolism. J  Thromb  Haemost 2011;9(2):300-304. 
(44) Roy P, Colombet I, Durieux P, Chatellier G, Sors H, Meyer G. Systematic review and 
meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. B M J 
2005;331:259. 
(45) Chunilal SD, Eikelboom JW, Attia J, Miniati M, Panju AA, Simel DL, et al. Does this 
patient have pulmonary embolism? J A M A 2003;290:2849-2858. 
(46) Worsley DF, Alvali A, Aronchick JM, Chen JT, Greenspan RH, Ravin CE. Chest 
radiographic findings in patients with acute pulmonary embolism: Observations from the 
PIOPED study. Radiology 1993;189:133-136. 
(47) Schoepf JU, Goldhaber SZ, Costello P. Spiral computed tomography for acute 
pulmonary embolism. Circulation 2004;109:2160-2167. 
(48) Legnani C, Palareti G, Cosmi B, Cini M, Tosetto A, Tripodi A. Different cut-off 
values of quantitative D-Dimer methods to predict the rist of venous thrombo-embolism 
recurrence: A post-hoc analysis of the PRONLONG study. Haematologica 
2008;93(6):900-907. 
(49) Duran-Mendicuti A, Sodickson A. Imaging evaluation of the pregnant patient with 
suspected pulmonary embolism. International Journal of Obstetric Anesthesia 2011;20:51-
59. 
 92 
 
(50) Kline JA, Hogg MM, Courtney DM, Miller CD, Jones AE, Smithline HA, et al. D-
Dimer and exhaled CO2/O2 to detect segmental pulmonary embolism in moderate - risk 
patients. Am  J  Respir  Crit  Care  Med 2010;182:669-675. 
(51) Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical 
computed tomography in the diagnosis of pulmonary embolism: A systematic review. 
Ann  Intern  Med 2000;132:227-232. 
(52) Gopinath A, Gildes TR. Pulmonary embolism. Available at: 
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/pulmonary/p. 
Accessed 16/01, 2011. 
(53) Pesavento R, de Conti G, Minotto I, Filippi L, Mongiat M, de Faveri D, et al. The 
value of 64-detector row computed tomography for the exclusion of pulmonary embolism. 
Thromb  Haemost 2011;105(5):901-907. 
(54) Kluge A, Mueller C, Strunk J, Lange U, Bachmann G. Experience in 207 combined 
MRI examinations for acute pulmonary embolism and deep vein thrombosis. 
AJR  Am  J  Roentgenol 2006;186:1686-1696. 
(55) Douma RA, Le Gal G, Sohne M, Righini M, Kamphuisen PW, Perrier A, et al. 
Potential of an age adjusted D-Dimer cut-off value to improve the exclusion of pulmonary 
embolism in older patients. A retrospective analysis of three large cohorts. B M J 
2010;340:1-7. 
(56) Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute 
pulmonary embolism: A meta-analysis. Circulation 2007;116(4):427-433. 
 93 
 
(57) Gutte H, Mortensen J, Jensen CV, Von Der Recke P, Petersen CL, Kristoffersen US, 
et al. ANP, BNP and D-Dimer predict right ventricular dysfunction in patients with acute 
pulmonary embolism. Clin  Physiol  Funct  Imaging 2010;30(6):466-472. 
(58) Stein PD, Janjua M, Matta F, Alrifai A, Jaweesh F, Chughtai HL. Prognostic value of 
D-Dimer in stable patients with pulmonary embolism. Clin  Appl  Thromb  Hemost 
2011;17(6):E183-185. 
(59) Sheares KK. How do I manage a patient with suspected acute pulmonary embolism? 
Clin  Med 2011;11(2):156-159. 
(60) Bajc M, Jonson B. Ventilation/Perfusion SPECT for Diagnosis of Pulmonary 
Embolism and Other Diseases. Int  J  Mol  Imaging 2011;2011:1-10. 
(61) Galle C, Papazyan JP, Miron MJ, Slosman D, Bounameaux H, Perrier A. Prediction 
of pulmonary embolism extent by clinical findings, D-Dimer level and deep vein 
thrombosis shown by ultrasound. Thromb  Haemost 2001;86:1156-1160. 
(62) Michiels JJ, Gadisseur A, Van Der Planken M, Schroyens W, De Maeseneer M, 
Hermsen JT, et al. A critical appraisal of non-invasive diagnosis and exclusion of deep 
vein thrombosis and pulmonary embolism in outpatients with suspected deep vein 
thrombosis or pulmonary embolism: How many tests do we need? Int  Angiol 
2005;24(1):27-39. 
(63) Michiels JJ, Pattynama PM. Exclusion and diagnosis of pulmonary embolism by a 
rapid ELISA D-Dimer test and non-invasive imaging techniques within the context of a 
clinical model. Clin  Appl  Thromb  Hemost 2000;6(1):46-52. 
 94 
 
(64) Yoon H, Gimber LKH, Takahashi JM. Reply Re: A prospective evaluation of a 
quantitative D-Dimer assay in the evaluation of acute pulmonary embolism. Journal of 
Vascular and Interventional Radiology 2008;19(12):1793-1794. 
(65) Kruip MJ, Leclercq MGL, Van Der Heul C, Prins MH, Buller HR. Diagnostic 
strategies for excluding pulmonary embolism in clinical outcome studies. Annals of 
Internal Medicine 2003;138(12):941-951. 
(66) Kline JA, Runyon MS, Webb WB, Jones AE, Mitchell AM. Prospective study of the 
diagnostic accuracy of the simplify D-Dimer assay for pulmonary embolism in emergency 
department patients. Available at: http://www.chestjournal.org/content/129/6/1417.full. 
Accessed 29/03, 2011. 
(67) D-Dimer. Available at: http://en.wikipedia.org/wiki/D-dimer. Accessed 03/29, 2011. 
(68) Douma RA, Kessels JB, Buller HR, Gerdes VE. Knowledge of the D-Dimer test 
result influences clinical probability assessment of pulmonary embolism. Thromb  Res 
2010;126(4):e271-e275. 
(69) Golledge J, Muller R, Clancy P, McCann M, Norman PE. Evaluation of the 
diagnostic and prognostic value of plasma D-Dimer for abdominal aortic aneurysm. 
Eur  Heart  J 2010;10:1093. 
(70) Hayashi S. Significance of plasma D-Dimer in relation to the severity of 
atherosclerosis among patients evaluated by non-invasive indices of cardio-ankle vascular 
index and carotid intima-media thickness. Int  J  Hermatol 2010;92(1):76-82. 
 95 
 
(71) Hong SK, Ko DW, Park J, Kim IS, Doo SH, Yoon CY, et al. Alteration of 
antithrombin III and D-Dimer levels in clinically localised prostrate cancer. 
Korean  J  Urol 2010;51(1):25-29. 
(72) Jovanovic M, Milic D, Djindjic B, Jovanovic J, Stanojevic G, Stojanovic M. 
Importance of D-Dimer testing in ambulatory detection of atypical and "silent" 
phlebothrombosis. Vojnosanit  Pregl 2010;67(7):543-547. 
(73) Arslan S, Ugurlu S, Bulut G, Akkurt I. The association between plasma D-Dimer 
levels and community-acquired pneumonia. Clinics 2010;65(6):1-7. 
(74) Roche Cardiac D-Dimer - Cardiac Reader. Cobas. Quantitative immunological test for 
the detection of D-Dimer in heparinised venous blood for use with the Cardiac reader 
instrument from Roche Diagnostics. 2006; Available at: www.roche.com. Accessed 03/29, 
2011. 
(75) Taira T, Taira BR, Carmen M, Chohan J, Singer AJ. Risk of venous thrombo-
embolism in patients with borderline quantitative D-Dimer levels. Am  J  Emerg  Med 
2010;28(4):450-453. 
(76) Goldin Y, Pasvolsky O, Rogowski O, Shapira I, Steinvil A, Halpern P, et al. The 
diagnostic yield of D-Dimer in relation to time from symptom onset in patients evaluated 
for venous thrombo-embolism in the emergency medicine department. 
J  Thromb  Thrombolysis 2011;31(1):1-5. 
(77) Ginsberg JS, Wells PS, Kearon C., et al. Sensitivity and specificity of a rapid whole 
blood assay for D-Dimer in the diagnosis of pulmonary embolism. Ann  Intern  Med 
1998;129:1006-1011. 
 96 
 
(78) British Thoracic Society. Guidelines for the management of suspected acute 
pulmonary embolism. Thorax 2003;58:470-484. 
(79) Brown MD, Rowe BH, Reeves MJ, Bermingham JM, Goldhaber SZ. The accuracy of 
the enzyme-linked immunosorbent assay D-Dimer test in the diagnosis of pulmonary 
embolism: A meta-analysis. Ann  Emerg  Med 2002;40:133-144. 
(80) Di Nisio M, Squizzato A, Rutjes AW, Buller HR, Zwinderman AH, Bossuyt PM. 
Diagnostic accuracy of D-Dimer test for exclusion of venous thrombo-embolism: A 
systematic review. J  Thromb  Haemost 2007;5:296-304. 
(81) Dunn KL, Wolf JP, Dorfman DM, Fitzpatrick P, Baker JL, Goldhaber SZ. Normal D-
Dimer levels in emergency department patients suspected of acute pulmonary embolism. 
J  Am  Coll  Cardiol 2002;40:1475-1478. 
(82) Schutgens RE, Haas FJ, Gerritsen WB, Van Der Horst F, Nieuwenhuis HK, Biesma 
DH. The usefulness of five D-Dimer assays in the exclusion of deep venous thrombosis. 
J  Thromb  Haemost 2003;1(5):976-981. 
(83) Kruip MJ, Slob MJ, Schijen JH, Van Der Heul C, Buller HR. Use of a clinical 
decision rule in combination with D-Dimer concentration in diagnostic workup of patients 
with suspected pulmonary embolism: A prospective management study. Arch  Intern  Med 
2002;162:1631-1635. 
(84) De Moerloose P, Desmarais S, Bounameaux H, Reber G, Perrier A, Dupuy G, et al. 
Contribution of a new, rapid, individual and quantitative automated D-Dimer ELISA to 
exclude pulmonary embolism. Thromb  Haemost 1996;75(1):11-13. 
 97 
 
(85) Wikipedia. Immunofluorescence. Available at: 
http://en.wikipedia.org/wiki/Immunofluorescence. Accessed 03/06, 2011. 
(86) IHCWORLD. Cell Biology Application of Fluorescence Microscopy. Available at: 
http://www.ihcworld.com/_protocols/immunofluorescence/fluorescende_microscopy. 
Accessed 03/06, 2011. 
(87) Scarano L, Bernardi E, Prandoni P, Sardella C, Rossi L, Carraro P, et al. Accuracy of 
two newly described D-Dimer tests in patients with suspected deep venous thrombosis. 
Thromb  Res 1997;86:93-99. 
(88) Sanchez LD, McGillicuddy DC, Volz KA, Fan S, Joyces N, Horowitz GL. Effect of 
two different FDA-approved D-Dimer assays on resource utilisation in the emergency 
department. Acad  Emerg  Med 2011;18(3):317-321. 
(89) Yeh KS, Tsai CE, Chen SP, Liao CW. Comparison between VIDAS automatic 
enzyme-linked fluorescent immunoassay and culture method for Salmonella recovery from 
pork carcass sponge samples. J  Food  Prot 2002;65(10):1656-1659. 
(90) Chang SS, Lee SH, Wu JY, Ning HC, Chiu TF, Wang FL, et al. Evaluation of the 
value of rapid D-Dimer test in conjunction with cardiac troponin I test for early risk 
stratification of myocardial infarction. J  Thromb  Thrombolysis 2010;30(4):472-478. 
(91) Franchi L, Patrelli TS, Berretta R, Rolla M, Gizzo S, Gramellini D, et al. Role of D-
Dimer testing in severe pelvic inflammatory disease: A new usable marker to assess the 
need for fertility impairing surgery? Fertil  Steril 2010;94(6):2372-2375. 
 98 
 
(92) Khaleghi M, Saleem U, McBane RD, Mosley TH, Kullo JJ. African American 
ethnicity is associated with higher plasma levels of D-Dimer in adults with hypertension. 
J  Thromb  Haemost 2009;7(1):34-40. 
(93) Tita-Nwa F, Bos A, Adjei A, Ershler WB, Longo DL, Ferrucci L. Correlates of D-
Dimer in older persons. Aging  CLin  Exp  Res 2010;22(1):20-23. 
(94) Klok FA, Kruisman E, Spaan J, Nijkeuter M, Righini M, Aujesky D, et al. 
Comparison of the revised Geneva Score with the Well's rule for assessing clinical 
probability of pulmonary embolism. J  Thromb  Haemost 2008;6(1):40-44. 
(95) Boya C, Greco F, Ferrari A, Serafini O, Nicoletti M, Garofalo R, et al. The usefulness 
of the association of clinical probability, rapid plasma measurement of D-Dimer, 
compression echography of the lower limbs and echocardiography in the diagnosis of 
acute pulmonary embolism. Ital  Heart  J  Suppl 2000;1(1):116-121. 
(96) Tick LW, Nijkeuter M, Kramer MH, Hovens MM, Buller HR, Leebeek FW, et al. 
High D-Dimer levels increase the likelihood of pulmonary embolism. J  Int  Med 
2008;264(2):195-200. 
(97) Michiels JJ, Gadisseur A, Van Der Planken M, Schroyens W, De Maeseneer M, 
Hermsen JT, et al. Different Accuracies of Rapid Enzyme-Linked Immunosorbent, 
Turbidimetric, and agglutination D-Dimer assays for thrombosis exclusion: Impact on 
diagnostic work-ups of outpatients with suspected deep vein thrombosis and pulmonary 
embolism. Semin  Thromb  Hemost 2006;32:678-693. 
 99 
 
(98) Hoo GW, Vazirani S, Li Z, Barack BM. Does a clinical decision rule using D-Dimer 
level improve the yield of pulmonary CT angiography? AJR  Am  J  Roentgenol 
2011;196(5):1059-1064. 
(99) Fumeaux T, Cornuz J. The use of the rapid D-Dimer test for the exclusion of acute 
venous thrombo-embolism in a regional hospital. Swiss  Med  Wkly 2003;133:178-183. 
(100) Froehling DA, Daniels PR, Swensen SJ, Heit JA, Mandrekar JN, Ryu JH, et al. 
Evaluation of a Quantitative D-Dimer Latex Immunoassay for acute pulmonary embolism 
diagnosed by computed tomographic angiography. Mayo  Clin  Proc 2007;85(5):556-560. 
(101) Agterof MJ, Schutgens RE, Moumli N, Eijkemans MJ, Van Der Griend R, Tromp 
EA, et al. A prognostic model for short term adverse events in normotensive patients with 
pulmonary embolism. Am  J  Hematol 2011;86(8):646-649. 
(102) Penaloza A, Melot C, Motte S. Comparison of the Wells score with the simplified 
revised Geneva score for assessing pre-test probability of pulmonary embolism. 
Thromb  Res 2011;127(2):81-84. 
(103) Wong DD, Ramaseshan G, Medelson RM. Comparison of the Wells and Revised 
Geneva scores for the diagnosis of pulmonary embolism: An Australian experience. 
Intern  Med  J 2011;41(3):258-263. 
(104) Bertoletti L, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, et al. 
Prognostic value of the Geneva prediction rule in patients in whom pulmonary embolism 
is ruled out. J  Intern  Med 2011;269(4):433-440. 
 100 
 
(105) Hogg K, Thomas D, Mackway-Jones K, Lecky F, Cruickshank K. Diagnosing 
pulmonary embolism: A comparison of clinical probability scores. Br  J  Haematol 
2011;153(2):253-258. 
(106) Singanayagam A, Scally C, Al-Khairalla MZ, Leitch L, Hill LE, Chalmers JD, et al. 
Are biomarkers additive to pulmonary embolism severity index for severity assessment in 
normotensive patients with acute pulmonary embolism? QJM 2011;104(2):125-131. 
(107) Hariharan P, Takayesu JK, Kabrhel C. Association between the Pulmonary 
Embolism Severity Index (PESI) and short-term clinical deterioration. Thromb  Haemost 
2011;105(4):706-711. 
(108) Courtney DM, Kline JA, Kabrhel C, Moore CL, Smithline HA, Nordenholz KE, et 
al. Clinical features from the history and physical examination that predict the presence or 
absence of pulmonary embolism in symptomatic emergency department patients: Results 
of a prospective, multicentre study. Ann  Emerg  Med 2010;55(4):307-315. 
(109) Sakamoto K, Yamamoto Y, Okamatsu H, Okabe M. D-Dimer is helpful for 
differentiating acute aortic dissection and acute pulmonary embolism from acute 
myocardial infarction. Hellenic  J  Cardiol 2011;52(2):123-127. 
(110) Turedi S, Karahan SC, Mentese A, Gunduz A, Topbas M, Kosucu P, et al. 
Investigation of relationship between the D-Dimer and ischemia-modified albumin levels 
with the radiological imaging-based pulmonary embolism severity score in acute 
pulmonary embolism - original investigation. Anadolu  Kardiyol  Derg 2010;10(4):346-
352. 
 101 
 
(111) Stein PD, Sostman HD, Dalen JE, Bailey DL, Bajc M, Goldhaber SZ, et al. 
Controversies in diagnosis of pulmonary embolism. Clin  Appl  Thromb  Hemost 
2011;17(2):140-149. 
(112) Drescher FS, Chandrika S, Weir ID, Weintraub JT, Berman L, Lee R, et al. 
Effectiveness and acceptability of a computerized decision support system using modified 
Well's criteria for evaluation of suspected pulmonary embolism. Ann  Emerg  Med 
2011;57(6):613-621. 
(113) Lee J, Zierier BK, Liu C, Chapko MK. Cost-effective diagnostic strategies in 
patients with a high, intermediate, or low clinical probability of pulmonary embolism. 
Vasc  Endovascular  Surg 2011;45(2):113-121. 
(114) Gallerani M, Imberti D, Ageno W, Dentali F, Manfredini R. Higher mortality rate in 
patients hospitalised for acute pulmonary embolism during weekends. Thromb  Haemost 
2011;106(1):83-89. 
(115) Courtney, D.M., Kline, J.A., Kabrhel, C., Moore, C.L., Smithline, H.A., Nordenholz, 
K.E., et al. Clinical features from the history and physical examination that predict the 
presence or absence of pulmonary embolism in symptomatic emergency department 
patients: results of a prospective, multi-center study. Ann  Emerg  Med 2010;55(4):307-
315. 
(116) Lucassen WAM, Douma RA, Toll DB, Buller HR, Van Weert HCPM. Excluding 
pulmonary embolism in primary care using the Wells-rule in combination with a point-of 
care D-dimer test: a scenario analysis. BMC Family Practice 2010;11(64):1471-2296. 
  
